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 Iron, an essential nutrient for most microorganisms, is sequestered in the host by iron-
binding proteins, such as lactoferrin and transferrin.   Neisseria gonorrhoeae utilizes transferrin 
as an iron source and its iron acquisition system is composed of two transferrin binding proteins: 
TbpA and TbpB.  TbpA is a TonB-dependent, outer membrane transporter and TbpB is a 
bilobed, surface exposed lipoprotein.  TbpB can distinguish between apo- and holo-transferrin 
which is involved in increasing the efficiency of iron uptake through the Tbps.  It is anchored in 
the outer leaflet of the outer membrane by its lipid moiety.  We aimed to identify the mechanism 
of TbpB export to the cell surface.  No conclusions could be made from our results but we 
identified a protein that could potentially be involved in lipoprotein transport.  TbpB is a bilobed 
protein with controversy over which lobe is involved in transferrin binding.  In this study, we 
xv 
 
constructed a C-lobe deletion of TbpB to determine the role of the C-lobe in TbpB function.  
Results presented here showed deletion of the C-lobe caused degradation of TbpB and the 
minimal protein expressed was unable to bind transferrin both in vitro and in vivo.  We were also 
able to demonstrate the TbpB C-lobe deletion is able to support limited transferrin-mediated 
growth, indicating some function of TbpB is retained.  These results confirmed that both lobes 
are necessary for wild-type function of TbpB. 
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CHAPTER 1:  Introduction 
 
Neisseria gonorrhoeae was first identified as the causative agent of gonorrhea and named 
by Albert Neisser in 1879.  However, gonorrhea, meaning “flow of seed”, has been around since 
well before that with many references throughout history, including the Bible (Leviticus 15) and 
observations made by Hippocrates.  The prevalence of gonorrhea has also led to the development 
of several nicknames including “the drip” and “the clap”, from the French word clapoir, meaning 
brothel.  The advent of antibiotic therapy in the 1930s and ‘40s led to a rapid decrease in 
gonorrhea prevalence.  However, recent increases in sexually transmitted diseases as well as the 
emergence of antibiotic resistance confirm the importance of further investigation into the 
pathogenesis of this disease. 
 
I.  The Genus Neisseria 
 The family Neisseriaceae is comprised of the genera Neisseria, Moraxella, 
Acinetobacter, and Kingella (101).  They are classified as aerobic, Gram-negative bacteria and 
are distinguished by their cell morphology as well as their ability to perform several biochemical 
processes.   
 The genus Neisseria contains species that are normal flora and pathogens to humans and 
animals.  A number of biochemical tests are used to differentiate between them, including acid 
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production, nitrate reduction, and the production of polysaccharide from sucrose.  DNase, 
oxidase, and catalase activities are also used to identify the species.  These tests are also used to 
differentiate Neisseria species from Moraxella and Kingella species (28, 101, 144).  Neisseria 
species have a diplococcus morphology with adjacent flattened sides and range from 0.6 to 1.5 
m in size.  The optimal growth conditions for Neisseria ranges between 35 and 37°C in the 
presence of 5% CO2.  Neisseria species colonize the mucous membranes of the nasopharynx, 
eyes, and urogenital tract.   
 The genus contains two obligate human pathogens:  N. gonorrhoeae and N. meningitidis.  
Both species are facultative intracellular bacteria but N. meningitidis is the only Neisseria species 
that produces an antiphagocytic capsule.  While N. gonorrhoeae is never part of the normal flora, 
N. meningitidis can be carried as normal flora of the nasopharynx.  However, invasive 
meningococcal disease can occur following colonization, for unknown reasons, causing bacterial 
meningitis and meningococcemia.  Although these pathogens are closely related, they cause very 
different diseases and clinical manifestations. 
 
II.  Meningococcal Disease 
A.  Epidemiology 
 First described by Anton Weischselbaum in 1887, Neisseria meningitidis is a leading 
cause of bacterial meningitis and other serious infections, causing significant morbidity and 
mortality worldwide.  Vieusseaux reported the first definitive identification of meningococcal 
disease in 1805 when an outbreak occurred in Geneva, Switzerland (170, 187, 210).  Since then, 
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the different serogroups and genetic variability of the meningococcus have continued to allow 
outbreaks of the disease. 
 Virulent N. meningitidis strains have a polysaccharide capsule that is used to classify 
them into serogroups.  Of the 13 serogroups that have been identified to date, only 5 (A, B, C, 
W-135, and Y) are responsible for causing more than 90% of meningococcal disease worldwide 
(35, 80).  Additionally, serogroup X has recently been reported to cause a significant amount of 
disease in sub-Saharan Africa (22, 79).  Serogroup A is responsible for some of the largest, most 
devastating epidemics that occur primarily along the “meningitis belt” in sub-Saharan Africa 
every 8 to 10 years (73, 80).  In the United States, serogroups B, C, and Y cause the majority of 
the disease with each accounting for approximately one third of the cases (36). 
Another important factor of meningococcal disease is that the etiological agent, N. 
meningitidis, can be carried as a commensal.   Approximately 10% of the population are carriers 
of N. meningitidis with the highest rate of carriage in adolescents and young adults, and the 
lowest in young children (34, 187).  However, carriage is highly variable with some individuals 
being carriers for many months while others are transient or intermittent carriers (80, 187, 242).  
Rates of transmission and carriage increase in populations living in confined areas such as 
college students and military personnel during epidemics (35, 187, 242).   
B.  Infection 
 Transmission occurs by person-to-person contact through the exchange of respiratory 
droplets or saliva.  Following colonization of the mucosal surfaces of the respiratory tract, 
invasive meningococcal disease develops when the bacteria cross the epithelium and enter the 
bloodstream causing meningococcemia.  Symptoms include sudden onset of fever and a 
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petechial or purpuric rash, and can result in hypotension, acute adrenal hemorrhage, multiorgan 
failure, shock, and death (118, 170).  The bacteria can also cross the blood-brain barrier resulting 
in meningitis.  Clinical manifestations include headache, fever, stiff neck, nausea, vomiting, 
photophobia, and altered mental state (118, 170).  Meningococcal meningitis is often 
distinguished from other bacterial meningitis infections by the rash that is indicative of an 
associated meningococcemia, although meningitis can develop independently (176).   Symptoms 
can appear quickly or develop 3-7 days after exposure.  Long term neurological sequelae, such as 
hearing loss, loss of limbs, mental retardation, and paralysis, can arise following a 
meningococcal infection (118).  Even with today’s medical advances and treatments, fatality 
rates in industrialized nations range from 5 to 10% while fatality rates in developing countries 
can reach up to 20% (230). 
C.  Treatment and Prevention 
 Since severe and debilitating symptoms can develop quickly, rapid diagnosis and 
treatment is critical.  Penicillin or ceftriaxone are the recommended treatments of meningococcal 
disease even though some penicillin resistance has been reported (80, 188).  For prevention, 
there are two kinds of quadrivalent meningococcal vaccines available in the United States: 
meningococcal polysaccharide vaccine (MPSV4) and meningococcal conjugate vaccine 
(MCV4).  Both kinds protect against serogroups A, C, Y, and W-135.  There is currently no 
vaccine against serogroup B.  Available since the 1970s, MPSV4 contains purified 
polysaccharide product and is the only licensed meningococcal vaccine for people older than 55 
years of age but does not confer long-lasting immunity (36).  MCV4 contains polysaccharide 
conjugated to diphtheria toxoid and is the preferred vaccine for people ages 2 to 55 (36, 79).  
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Despite having multiple vaccines and treatment options available, meningococcal disease 
continues to be a global public health problem. 
 
III.  Gonococcal Disease 
A.  Epidemiology 
 Gonorrhea is the second most common reportable infection in the United States.  In 2010, 
309,341 cases were reported in the U.S. with a rate of 100.8 per 100,000 population, a slight 
increase from the previous year (37).  However, due to underreporting, the Centers for Disease 
Control and Prevention estimates that this number is less than half the actual number of 
infections which is greater than 700,000 (37).  Global incidence of gonorrhea is estimated to be 
62 million infected people annually (231). 
 Disparities in gonococcal infection rates exist among age, sex, ethnic, and socioeconomic 
groups.  Adults aged 20-24 years have the highest incidence of infections with rates in women 
higher than in men (37).  As in previous years, gonorrhea rates were highest in the South, 
corresponding with the nation’s highest poverty rates, and among African Americans with rates 4 
times the national average (37). 
B.  Infection 
 N. gonorrhoeae infects the non-ciliated epithelial cells of the mucosal membranes, with 
the urethra in men and endocervix in women being the primary sites.  Transmission occurs 
through intimate sexual contact and ejaculation does not have to occur.  Gonococcal infections in 
men are typically symptomatic, occurring as an acute urethritis.  Symptoms usually appear 1 to 
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14 days after infection and include purulent discharge and dysuria.  However, asymptomatic 
infections can occur and serious complications, such as epididymitis, prostatitis, and infertility, 
can develop if left untreated.   
 In women, N. gonorrhoeae infections generally present with no or mild symptoms, with 
some estimates that up to 80% of infected women are asymptomatic.  If symptoms emerge, they 
occur within the first 10 days of infection and may consist of dysuria, urinary frequency, 
increased vaginal discharge, and vaginal bleeding between periods.  When left untreated, serious 
complications can occur as a result of the ascension of the microorganism into the upper genital 
tract and infection of the fallopian tubes and uterus.  This causes pelvic inflammatory disease 
(PID) which may lead to scarring of the fallopian tubes, ectopic pregnancy, and infertility.   
 Other sites that can be infected are the conjunctiva, pharynx, and rectal mucosa.  
Anorectal infection in both men and women is usually asymptomatic but can present symptoms 
of proctitis, including anal itching, discharge, soreness, bleeding, constipation, and painful bowel 
movements (100).  Throat infections are also usually asymptomatic but can cause a sore throat 
and are an important reservoir of the gonococcus (232).  Adult gonococcal conjunctivitis is 
characterized by redness, burning or irritation, discharge, and inflammation of the eyes which, if 
left untreated, can result in corneal scarring, perforation, and vision loss (134, 218).  Neonates 
can also contract gonococcal conjunctivitis through vertical transmission from the mother during 
birth, resulting in similar symptoms (237).   
Disseminated gonococcal infection (DGI) develops in approximately 0.5-3% of all 
gonococcal infections.  Classic symptoms include fever, dermatitis, and arthritis but rare, serious 
complications can occur including endocarditis and meningitis (88).  People infected with 
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gonorrhea frequently are coinfected with Chlamydia trachomatis.  Additionally, infection with 
N. gonorrhoeae increases the transmission of HIV through the induction of viral RNA 
expression (40) and increased shedding of HIV in semen (45) and cervical secretions (126) due 
to inflammation. 
C.  Treatment 
 Effective antibiotic treatment is essential for the treatment and control of gonorrhea.  
However, N. gonorrhoeae has developed resistance to almost all antibiotics used for treatment.  
Sulfonamides were introduced as the first antimicrobial for treatment of gonorrhea in the mid-
1930s (97).  The bacteria quickly became resistant to sulfa drugs with widespread resistance by 
the mid-1940s (60).  Fortunately, in 1943, penicillin was identified as highly effective against 
gonococci and became the treatment choice for several decades (97, 119, 209).  N. gonorrhoeae 
began developing low level resistance to penicillin over the next 30 years due to the sequential 
accumulation of chromosomal mutations (229).  Additionally, high level plasmid-mediated 
resistance was reported in several countries in 1976 (8, 150).  Coincident with the development 
of penicillin resistance, gonococci also developed resistance to several other antibiotics, 
including aminoglycosides, macrolides, and tetracycline (206).  Subsequently, fluoroquinolones, 
such as ciprofloxacin, were recommended as the first line of therapy from the mid-1980s until 
2007 when the CDC removed them from the recommended treatment regimen due to resistance 
(38).  Only one class of antimicrobials remains as the recommended and available treatment of 
gonorrhea: the third generation cephalosporins (37).  However, resistance to cephalosporins is on 
the rise with the first high level clinical resistance identified in early 2011 (147).  Gonococcal 
infection does not elicit protective immunity so reinfection can occur, and there is no vaccine to 
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prevent infection with N. gonorrhoeae.  With no vaccine and diminishing treatment options, 
gonorrhea may become untreatable. 
 
IV.  Gonococcal Virulence Factors 
 Neisseria possess a wide array of virulence factors, most of which are on the bacterial 
cell surface.  These outer membrane proteins play a role in cell colonization and invasion, as well 
as evasion of the host immune response.  Their ability to modulate these surface antigens through 
phase and antigenic variation further enable the bacteria to cause infection, by modifying their 
surface antigens and expressing factors based on environmental signals.  Virulence factors are 
essential for gonococcal pathogenesis and successful infection of the human host. 
A.  Pilus 
 The type IV pilus is an important virulence factor in N. gonorrhoeae and plays a role in 
several key functions.  Pili are filamentous cell surface structures that are comprised of two main 
proteins, PilE and PilC.  PilE is the major pilin subunit that polymerize into a helical cylinder to 
form a filament 1,000-4,000 nm long and 6 nm in diameter (148).  PilC is an essential assembly 
factor at the base of the pilus (95), as well as an adhesion located at the tip (173). 
The pilus is highly variable due to both antigenic and phase variation with a frequency of 
about 10
-3
 per cell per generation (53).  Antigenic variation results from the unidirectional DNA 
recombination from silent gene copies (pilS) into the pilin expression (pilE) locus (75, 76, 129).  
PilE also undergoes phase variation due to a poly-cytosine (C) tract located at the beginning of 
the pilE gene that causes a frame shift during DNA replication, turning the gene on/off (102).  
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Similarly, PilC is subject to phase variation but due to a poly-guanine (G) tract (95).  Pilin can 
also undergo post-translational modifications including glycosylation (211) and addition of a 
phosphorylcholine (85).     
The first step in bacterial infection is initial attachment to host cells which is mediated by 
the pilus in neisserial infections (189, 196).  Pili aid in overcoming the electrostatic repulsive 
barrier between the gonococci and host cells (84) as well as adherence to the host cell surface.  
Several potential receptors have been indicated to bind pili, including CD46 (96), C4 binding 
protein (21), and complement receptor 3 (61).  The importance of the pilus was demonstrated in 
previous studies that showed only piliated gonococci were able to establish infection in human 
males while non-piliated gonococci were unsuccessful (98).  Pili also play a role in twitching 
motility which is accomplished through filament retraction (128) and may provide a mechanism 
by which non-motile gonococci can colonize and ascend mucosal surfaces (216).  Additionally, 
gonococci are naturally competent and pili play a role in the uptake of DNA, increasing the 
transformation frequency of the gonococci (16, 184).  
B.  Opacity proteins 
 Opacity (Opa) proteins are a family of integral outer membrane proteins that function as 
adhesins.  Their name refers to the color and opacity changes of bacterial colonies observed with 
expression of these proteins (197).  Although they are expressed in greater number in pathogenic 
Neisseria, some commensal Neisseria species are also capable of expressing Opa proteins (236).  
The predicted structure of these proteins is comprised of four surface-exposed loops and eight 
transmembrane domains (120).  Opacity proteins are important virulence factors during 
gonococcal infection because strains isolated from infected individuals are usually Opa
+
 (198).  
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Additionally, Opa
+
 isolates were recovered from male volunteers that were inoculated with Opa
-
 
variants (92). 
 N. gonorrhoeae can possess as many as 11 unlinked chromosomal alleles that encode 
distinct Opa variants (13), while N. meningitidis only has 3-4 alleles (190).  In the gonococci, up 
to 4 Opas can be expressed at any given time due to high frequency phase variation (19).  This is 
due to slipped-strand mispairing during replication which causes variations in the number of 
CTCTT repeats, resulting in a translational frame shift (138).   
 Opas are some of the proteins responsible for tight adherence of the bacteria to the host 
cell surface after the initial attachment of the pili.  Two host cell surface molecules have been 
identified to bind Opas:  heparin sulfate proteoglycans (HSPG) and carcinoembryonic antigen-
related cell adhesion molecules (CEACAMs).  A subset of Opas bind HSPG, and vitronectin in 
some cases, to activate bacterial cell uptake through several mechanisms dependent on the cell 
type (68).  However, most of the Opas bind CEACAMs to mediate invasion into cells such as 
neutrophils (44).  Binding of Opas to CEACAMs on epithelial cells causes cytoskeletal 
rearrangements leading to internalization of the gonococci (72) and transcytosis across a 
polarized monolayer (220).  This interaction is significant because more than 95% of mucosal 
and clinical isolates of meningococci and gonococci bind a CEACAM (212). 
C.  Porin 
Porins are the most abundant outer membrane protein in the pathogenic Neisseria 
species.  They function as voltage-dependent aqueous pores for the exchange of ions and are 
essential for bacterial survival (244).  Porins form a predicted -barrel structure with eight 
surface-exposed loops and assemble in the membrane as a trimeric complex (59, 207).  While N. 
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meningitidis expresses two types of porins, PorA and PorB, (64), N. gonorrhoeae only expresses 
a PorB homolog (137).  The gonoccocal PorB is further classified into two groups, PIA and PIB, 
based on biochemical and immunological criteria (71).   
Multiple roles in disease progression have been attributed to porin proteins, aiding in both 
cell invasion and immune evasion.  A unique feature of neisserial porins is their ability to 
translocate into eukaryotic cell membranes (115, 223).  They act as voltage-gated channels on 
the target cell surface and are modulated by cytoplasmic ATP and GTP (174).  PorB has been 
found to cause target cell apoptosis by inducing a rapid calcium influx and activating calpain and 
caspase activity (136).  In addition, porins act as actin-nucleating proteins in epithelial cells, 
facilitating cytoskeletal rearrangements and actin-mediated entry of the bacteria (224).  Porins 
have also been associated with inhibiting phagosome maturation in macrophages (135) as well as 
neutrophil degranulation, opsonin receptor expression, and phagocyctosis (18).  Serum resistance 
is conferred by porins by down regulating both the classical and alternative complement 
pathways by binding to the C4b binding protein and factor H, respectively (158, 159). 
D.  Lipooligosaccharide 
 Lipopolysaccharide (LPS) is the main component of the outer leaflet of the outer 
membrane in Gram-negative bacteria.  It contributes to the structural integrity of the membrane 
and also acts as an endotoxin.  LPS is comprised of a lipid A moiety that anchors LPS to the 
membrane, a core domain of oligosaccharides that attach directly to the lipid A, and an O-
antigen polysaccharide side chain.  Neisseria produce a truncated version, lipooligosaccharide 
(LOS), of this molecule that lacks the repetitive O-antigen side chains due to a highly branched 
core oligosaccharide structure.  During LOS synthesis, glycosyl transferases are responsible for 
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the addition of sugar groups to the -chain.  These transferases are subject to phase variation 
which causes changes in the LOS size and structure, leading to antigenic variations of the LOS 
(55).  Poly-G tracts within the transferase genes are responsible for slipped strand mispairing and 
the phase variation (241).   
 LOS can also undergo external modification by sialic acid modification.  A gonococcus-
encoded sialyltransferase present in the outer membrane mediates sialylation using host-derived 
cytidine 5’-mono-phospho-N-acetylneuraminic acid (CMP-NANA) as the sialyl donor (121, 
140).  The sialylation of LOS contributes to serum resistance by binding factor H and inhibiting 
alternative complement pathway (160).  However, the presence of sialic acid on LOS also 
impairs cellular invasion into some cell types, suggesting that LOS variation may allow the 
gonococci to fluctuate between invasive and serum-resistant phenotypes to promote bacterial 
survival (208). 
E.  Reduction-modifiable protein 
 Reduction-modifiable protein (Rmp) is a surface exposed outer membrane protein that 
exhibits a high degree of homology between strains (116).  Rmp was named for the molecular 
weight shifts observed after SDS-PAGE analysis in reducing conditions and shares partial 
homology with the enterobacterial OmpA protein (69, 70).  It is intimately associated with porin 
and LOS in the gonococcal membrane (20, 86, 127).  Antibodies generated against Rmp block 
binding of antibodies against porin and LOS, inhibiting complement-mediated killing of the 
gonococci (94, 165).  This impairs the immune response and increases the host susceptibility to 
infection (154). 
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F.  IgA1 protease 
 Immunoglobulin A (IgA) is the predominant antibody on human mucosal surfaces and 
pathogenic Neisseria secrete a serine protease specific to IgA1, an IgA subtype.  This protease 
cleaves IgA1 antibodies into the F(ab) and FC fragments which are involved in antigen binding 
and effector function, respectively (153).  The F(ab) fragment is thought to bind the bacterial cell 
surface and coat antigenic determinants, blocking antibody binding sites and epitopes from the 
immune system.  IgA1 protease has also been demonstrated to cleave LAMP1, a major 
membrane protein of late endosomes and lysosomes, promoting phagosomal escape and 
intracellular survival of the gonococci (82, 112).  The protease may furthermore play a role in the 
traversal of epithelial barriers as it was shown to be involved in N. gonorrhoeae trafficking 
across polarized epithelial monolayers (89).  However, in a human challenge model, mutants 
lacking IgA1 protease were indistinguishable from wild-type strains, indicating that it is not 
involved in gonococcal colonization and establishment of infection in males (93).  Thus, IgA1 
protease likely only plays a role in immune evasion and intracellular survival of the bacteria. 
 
V.  Iron Sources and Transport in the Human Host 
 For most living organisms, iron is an essential nutrient that plays a pivotal role in many 
growth and metabolic processes, including electron transport, DNA and amino acid synthesis, 
and photosynthesis (219).  Despite its abundance in the environment, the bioavailability of iron is 
limited due to its physical properties.  Under aerobic conditions, iron is primarily found in its 
oxidized ferric form (FeIII), which is insoluble and aggregates into oxy-hydroxide polymers 
(219).  The more soluble, reduced form, ferrous iron (FeII), can react with reduced forms of 
14 
 
oxygen, such as hydrogen peroxide, to generate free hydroxyl radicals by the Fenton reaction 
(29).  These cause oxidative stress leading to damage of cellular macromolecules, tissue injury, 
and disease (221).  Therefore, iron homeostasis is strictly regulated in the human body through 
intracellular storage and carrier proteins. 
A. Transferrin 
 Transferrin (Tf) is the most abundant iron transport protein in humans and plays a crucial 
role in controlling free iron levels in the body as well as delivering iron to cells.  It is a 80 kDa 
monomeric glycoprotein that has two structurally similar domains, the N-terminal domain or N-
lobe and the C-terminal domain or C-lobe.  Each lobe is further divided into subdomains (N1 and 
N2, C1 and C2) connected by a hinge that forms a deep, hydrophilic cleft for iron-binding (217).  
Transferrin can theoretically bind two atoms of iron but it is only 30% saturated in the body and 
preferentially binds iron in the N-lobe (235).  It has a high affinity for iron with a binding 
constant of 10
-22
 M (1) which is pH (39) and salt concentration dependent (234).  Transferrin is 
synthesized in the liver and secreted into the serum but is also found in other bodily fluids.  It 
transports iron from the gut to iron-depleted cells where it binds to transferrin receptors on the 
cell surface.  The whole complex is then internalized and transported to the endosome where a 
decrease in the pH promotes iron release.  Both the transferrin protein and transferrin receptor 
are recycled to the cell surface. 
B.  Lactoferrin 
 Comparable to transferrin, lactoferrin is a single-chain, bilobed glycoprotein with a 
molecular weight of about 80 kDa.   The most abundant source of lactoferrin is milk but it is also 
found in other bodily fluids, secondary granules of neutrophils, and on mucosal surfaces.  
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Although the affinity of lactoferrin for iron is 300 times greater than transferrin, it is only 6 to 
8% saturated in human milk (177).  Lactoferrin’s antimicrobial activity has long been recognized 
and attributed to its ability to sequester iron, making it unavailable to pathogens.  However, a 
secondary antibacterial mechanism has also been described that is independent of iron-binding 
(30, 31, 63).  It is mediated through the direct interaction between the pathogen and lactoferrin or 
lactoferricins, derived peptides that are more potent than the intact protein (12, 63), which 
disrupts the bacterial cell membrane (240).  Lactoferrin also has a role in transcriptional 
regulation (122), immunoregulation, and inhibition of tumor growth (31). 
C.  Ferritin 
 Ferritin is the primary intracellular iron storage protein in the human body and is present 
in most cell types.  Ferritins are a large class of ubiquitous iron storage proteins found in many 
organisms including other vertebrates, invertebrates, plants, fungi, and bacteria (202).  Ferritin is 
a globular protein consisting of 24 subunits that forms a hollow protein shell with an iron core 
that is capable of storing up to 4,500 FeIII atoms (81).  It is composed of two kinds of subunits, 
H and L, with molecular weights of 21 kDa and 19 kDa, respectively (7).  By binding iron in its 
ferric form, ferritin maintains it in a soluble, available form for use in cellular functions while 
protecting the cell from the toxic effects of ferrous iron. 
D.  Heme binding proteins 
 Heme is a prosthetic group that consists of an iron atom in the center of a porphyrin ring.  
It is involved in the function of many proteins with a diverse range of functions.  Because of its 
cytotoxicity, heme is rarely found in free form and is usually associated with hemoproteins such 
as hemoglobin.  Found in red blood cells, hemoglobin is a globular protein consisting of four 
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subunits, each with a heme group.  Its main function is the delivery of oxygen and removal of 
carbon dioxide throughout the body.  Macrophages are mainly responsible for the metabolism of 
hemoglobin by engulfing senescent erythrocytes (104) but at least 10% of red cell breakdown is 
from intravascular hemolysis (66).  Ruptured erythrocytes release hemoglobin and heme into the 
plasma where its ability to catalyze hydroxyl-radical generation and cause oxidative stress is a 
potential hazard (175).  Additionally, nitric oxide, a critical regulator of vasodilation and 
vascular homeostasis, reacts with hemoglobin in a fast, irreversible reaction, limiting the 
bioavailability of nitric oxide (172).  Therefore, efficient removal of free hemoglobin and heme 
is essential and accomplished through the functions of two main proteins. 
 Haptoglobin is an acute phase plasma glycoprotein that binds to free hemoglobin, 
protecting against its toxic effects.  The haptoglobin-hemoglobin complex then binds to its 
specific receptor, CD163, on macrophages, mediating endocytosis of the complex (104).  After 
internalization, the globin moieties are degraded in the lysosome, heme is converted into less 
toxic compounds, and free iron is recycled (145).  Hemopexin is another plasma glycoprotein 
that protects against hemoglobin-mediated oxidative damage.  When free heme is released in the 
plasma during the breakdown of hemoglobin, hemopexin binds it and stimulates receptor-
mediated endocytosis in the liver where the heme is degraded, similarly to haptoglobin-
hemoglobin (56).  However, unlike haptoglobin, hemopexin is reutilized and returned intact to 
circulation (183). 
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VI.  Iron Acquisition Systems in Bacteria 
 Iron homeostasis is so tightly regulated in the human body that there is virtually no free 
iron.  Withholding essential nutrients is an important line of defense against bacterial infection.  
However, many bacteria have developed specialized mechanisms to obtain iron in the human 
host, including siderophore production, organic acid utilization, and host-iron binding protein 
receptors. 
 Many bacteria secrete siderophores, which are low molecular weight iron chelating 
molecules.  They have very high affinities for iron and can strip iron from host iron-binding 
proteins.  More than 500 different siderophores, produced by Gram-positive and Gram-negative 
bacteria, yeasts, and fungi, have been described (161, 219).  They are classified into three main 
groups based on their chemical nature:  hydroxyamates, catecholates, and hydroxyacids (62, 
219).  Some bacteria are also capable of producing hemophores which are functionally analogous 
to siderophores except they target and remove heme from host hemoproteins (182). 
 After binding to iron, ferrisiderophore complexes are transported into the bacterial cell 
through specific transport systems.  In Gram-negative bacteria, these systems are dependent on 
the TonB-ExbB-ExbD complex for energy and consist of an outer membrane receptor, 
periplasmic binding protein, and ATP-driven transporters in the cytoplasmic membrane (62).  
Siderophores produced by other microorganisms, xenosiderophores, may also be utilized as an 
iron source through these transport systems. 
 In addition to siderophores, some microbes have the ability to take up iron from organic 
acids like pyruvate and citrate (29).  The ability to use citrate as an iron source has been noted in 
several bacertia, including Shigella flexneri (114), N. meningitidis (6), and Escherichia coli (65).  
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In E.coli, the best described ferric citrate transport system, the outer membrane receptor, FecA, is 
necessary for ferric citrate uptake across the outer membrane (215).  The transport system also 
involves a periplasmic binding protein (FecB), two cytoplasmic membrane proteins (FecC and 
FecD), and a membrane-associated ATP-binding protein (FecE) (186).  It is dependent on the 
TonB-ExbB-ExbD complex for energy (245) and is regulated by the presence of citrate and iron 
(90). 
 Another method of iron acquisition is the utilization of host iron-binding proteins through 
receptors on the bacterial cell surface.  Receptors for these proteins, described below, have been 
identified in many bacteria including Helicobactor pylori (91), Staphylococcus aureus (78), and 
Haemophilus influenzae (179).  This mechanism of iron acquisition is well characterized in 
Neisseria and discussed in detail below. 
 
VII.  Iron Acquisition by Pathogenic Neisseria 
 Neisseria do not produce siderophores (227) but can utilize xenosiderophores aerobactin 
(226) and enterobactin (33).  N. gonorrhoeae can also use dihydroxybenzoylserine and 
salmochelins (195).   However, xenosiderophores are not available at all sites of infection and 
their concentrations may not be sufficient to support growth.  Therefore, Neisseria mainly rely 
on their ability to utilize host iron-binding proteins transferrin, lactoferrin, and hemoglobin as 
iron sources.  Each iron-binding protein has its own specific receptors on the bacterial cell 
surface but they are similar to each other, consisting of a TonB-dependent transporter and a 
lipoprotein. 
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 The lactoferrin iron acquisition system consists of two components: lactoferrin binding 
protein (Lbp) A and B.  LbpA is a TonB-dependent outer membrane transporter (17) and LbpB 
is a lipoprotein that, unlike LbpA, is not required for the utilization of human lactoferrin as an 
iron source (14).  However, due to a large deletion, only about 50% of clinical gonococcal 
isolates express the Lbps (4).  Neisseria are also able to use free heme and hemoglobin as iron 
sources (130).  No specific receptor has been identified for free heme but a two-component 
system, HpuAB, has been identified for hemoglobin and hemoglobin-haptoglobin in both N. 
gonorrhoeae and N.  meningitidis (41, 42, 109, 111).  In this system, HpuB is the TonB-
dependent outer membrane transporter and HpuA is the associated lipoprotein, both of which are 
required for the utilization of hemoglobin.  Additionally, a single component, TonB-dependent 
hemoglobin iron transporter, HmbR, was found only in N. meningitidis (192, 193).  Both of these 
hemoglobin iron acquisition systems undergo phase variation due to a poly-G tract (41, 110, 
166).   
 Most iron uptake systems are energy-dependent processes and require TonB-dependent 
transporters.  These systems rely on the TonB-ExbB-ExbD complex for this energy.  
Cytoplasmic membrane proteins ExbB and ExbD are thought to harness the proton-motive force 
that is generated across the cytoplasmic membrane.  This energy is then passed to TonB which 
spans across the periplasm, by an unknown mechanism, to physically interact with TonB-
dependent receptors in the outer membrane (99, 106, 131).  This interaction causes a 
conformational change in the transporter, resulting in the internalization of the substrate.  The 
TonB system in N. gonorrhoeae is essential for the utilization of host iron-binding proteins (48), 
as well as xenosiderophores in strain FA1090 (87).  The FbpABC system is responsible for 
transporting iron extracted from lactoferrin and transferrin across the periplasm and into the 
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cytoplasm (43).  However, the periplasmic binding protein and ABC transport system for iron 
extracted from hemoglobin has not yet been identified. 
 
VIII.  Transferrin Iron Acquisition System of Neisseria 
 The acquisition of iron from transferrin in the pathogenic Neisseria is dependent on a two 
component receptor complex.  It is comprised of two transferrin binding proteins, TbpA and 
TbpB.  These proteins are encoded by a bicistronic operon with the tbpB gene located upstream 
of tbpA (108, 169).  The genes are co-transcribed but a 86 base-pair intergenic region between 
the genes potentially forms a stem loop in the mRNA, resulting in differential expression of the 
genes with a 2:1 ratio of tbpB transcripts to tbpA transcripts (169).  The tbpBA promoter contains 
a Fur (ferric uptake regulator) binding site, a global regulator that represses gene transcription in 
the presence of iron (108, 203).  Therefore, the Tbps are preferentially expressed under iron-
restricted conditions and the presence of transferrin does not alter their expression (180, 181).   
 TbpA is an integral, outer membrane protein that forms a pore through which the iron is 
translocated across the membrane (49).  It is a TonB-dependent transporter with an N-terminal 
TonB box, demonstrating homology to other TonB-dependent transporters (49).  TonB 
specifically interacts with TbpA (99) and a TonB box mutant is capable of binding transferrin 
but defective in transferrin-iron uptake (48).  TbpA is essential for the utilization of transferrin as 
an iron source as mutants that do not express TbpA are capable of binding transferrin but 
incapable of growing on it (49, 51).  Recently, the crystal structure of N. meningitidis TbpA was 
solved, confirming the previously hypothesized 22-strand transmembrane -barrel pore and an 
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N-terminal plug domain (27, 146, 243).  The TbpA protein is highly conserved among 
pathogenic Neisseria strains (46). 
 The second component of the transferrin receptor complex, TbpB, is a surface exposed 
lipoprotein (5, 108).  Unlike TbpA, TbpB is not essential for transferrin-iron utilization (5) but is 
capable of binding transferrin and distinguishing between apo- and holo-transferrin (26, 51).  It is 
thought that this ability, along with its ability to affect the association and dissociation of 
transferrin (58), make the process of iron uptake more efficient.  Gonococcal mutants lacking 
TbpB are still able to bind transferrin but exhibit decreased iron uptake efficiency (5).   
The unfolded TbpB protein is recognized and translocated across the inner membrane by 
the Sec system through its N-terminal signal sequence (24).  TbpB also contains a signal 
peptidase II cleavage site and is able to be labeled with C
14
-palmitic acid, indicating that it is 
lipid modified (5).  It is fully surface exposed and tethered to the outer leaflet of the outer 
membrane by its lipid moiety (57).  However, the mechanism of TbpB transport across the 
periplasm to the outer membrane and its localization to the outer leaflet of the outer membrane is 
still unknown.  Internal homology of neisserial TbpB indicates a bilobed structure with several 
regions of identity between the N- and C-terminal halves (164).  This was confirmed by the 
resolution of the crystal structure of N. meningitidis TbpB (146).  Controversy remains as to 
whether only the N-lobe or both lobes are involved in binding transferrin and responsible for the 
function of Neisseria TbpB. 
Iron internalization from transferrin is initiated when a transferrin molecule binds to the 
TbpA and TbpB receptor complex (Figure 1).  TbpA is energized by the TonB-ExbB-ExbD 
complex through an interaction with its TonB box.  Iron is then stripped from transferrin,  
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Figure 1.  Schematic of the Neisseria transferrin iron acquisition system.  Human transferrin 
(Tf) can complex two atoms of iron.  The transferrin iron acquisition system is composed of two 
outer membrane (OM) proteins, transferrin binding protein (Tbp) A and B.  TbpA forms the pore 
through which iron enters into the cell and TbpB is a lipid modified accessory protein.  Iron 
internalization is an energy-dependent process which is supplied by the cytoplasmic inner 
membrane (IM) complex TonB-ExbB-ExbD through a TonB-TbpA interaction.  Once 
internalized, iron is bound by the periplasmic chaperone FbpA and shuttled across the periplasm 
(PP) to the FbpB-FbpC permease complex in the IM.  In an ATP-dependent step, iron is 
translocated into the cytoplasm.  
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presumably through interactions with the TbpA plug domain, and translocated into the 
periplasm.  The periplasmic binding protein, FbpA, binds the iron and shuttles it across the 
periplasm to the cytoplasmic membrane.  Here, the FbpB-FbpC permease complex transports the 
iron into the cytoplasm in an ATP-dependent step (Figure 1).   
 
IX.  Vaccine Development against N. gonorrhoeae 
 Vaccine development against N. gonorrhoeae has been challenging due to several 
factors.  The vaccine against N. meningitidis functions by eliciting bactericidal antibodies against 
the polysaccharide capsule, which N. gonorrhoeae does not produce.  Also, many potentially 
antigenic surface exposed proteins, such as pilin and opacity proteins, are subject to phase and 
antigenic variation.  Despite its highly variable nature, pilus was evaluated as a vaccine candidate 
with no success (25).  Porin, although not subject to phase or antigenic variation, was also 
unsuccessful as a vaccine candidate (228) due to LOS sialylation and Rmp antibodies blocking 
potential bactericidal activity of porin antibodies (165).   
The Tbps are promising vaccine candidates since they are not subject to high frequency 
phase or antigenic variation, are fully surface exposed, and are expressed in all clinical isolates 
(130).  Additionally, it has been shown that they are necessary for the establishment of infection 
in a human male challenge study (50).  Meningococcal Tbps elicit antibodies that are 
bactericidal, cross reactive against heterologous strains, and block transferrin utilization (152, 
191, 225).  However, it has been demonstrated that meningococcal TbpB alone is sufficient in 
producing a protective immune response (113, 151, 152, 168).  The protective role of TbpB has 
also been confirmed in Moraxella cartarrhalis (139), Actinobacillus pleuropneumoniae (171), 
25 
 
and Haemophilus influenzae (222).  Also, recombinant gonococcal Tbps conjugated to cholera 
toxin B subunit induced an antibody response in the serum and genital tract of female mice, with 
TbpB generating a greater response than TbpA (156).  Therefore, TbpB is a potential antigen for 
the development of an efficacious vaccine against N. gonorrhoeae.  
 
X.  Objectives 
 Understanding the structure and function of TbpB is crucial in delineating its potential as 
a vaccine candidate.  TbpB is entirely surface exposed and tethered to the outer leaflet of the 
outer membrane by its lipid moiety.  However, little is known about the export of TbpB to and its 
orientation in the outer membrane.  First, we sought to identify the mechanism of TbpB transport 
to the outer membrane and its localization to the outer leaflet of the outer membrane.  We 
employed mutagenesis using a transposon library to screen for deficiencies in transferrin 
utilization and potential TbpB export deficient mutant strains. 
TbpB has a bilobed structure, similar to human transferrin, and is able to bind transferrin 
independently of TbpA.  Previous studies analyzing transferrin binding showed differing results 
with in vitro recombinant protein studies attributing only the N-lobe with binding and in vivo 
studies with intact gonococci indicating the involvement of both lobes.  Secondly, we wanted to 
determine the role of the TbpB C-lobe in transferrin binding and iron stripping in vivo.  This was 
done through the generation and characterization of a TbpB C-lobe deletion protein in N. 
gonorrhoeae strains.  Identifying how the TbpB protein is exported to the outer leaflet of the 
outer membrane and determining the regions of TbpB required for function in vivo could provide 
insight into the pathogenesis of the organism and identify potential therapeutic targets. 
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CHAPTER 2:  Materials and Methods 
 
I.  Bacterial Growth Conditions 
 N. gonorrhoeae strains were maintained on GC medium base (GCB) (Difco) with 
Kellogg’s Supplement I (98) and 12 M Fe(NO3)3 (Supplement II) at 37°C and 5% CO2.  For 
iron-depleted liquid growth conditions, gonococci were grown in a defined media that was 
treated with Chelex 100 (Biorad) to remove any iron (CDM) (227).   Additionally, iron-deplete 
conditions were achieved by growth in GCB media containing Kellogg’s Supplement I.  After 
one mass doubling, Desferal (DFO) (50 M) was added to increase the iron stress.  All liquid 
cultures were grown at 37°C with 5% CO2 shaking at 220 rpm and allowed to grow for 4 hours 
after Desferal addition.  Iron-stress of plate-grown gonococcal strains was achieved by overnight 
growth on GCB with Kellogg’s Supplement I and 5 M DFO (Sigma) plates followed by 
resuspension in GCB media.  E. coli strains were maintained on Luria Bertani agar plates and 
grown in Luria Bertani (LB) media containing 100 g/ml of ampicillin for TOP10 cells and both 
100 g/ml of ampicillin and 34 g/ml of chloramphenicol for the BL21 (pLysS) cells at 37°C 
shaking at 225 rpm.   
 
 
 
27 
 
II.  Generation of Mutants using a Transposon Library 
 The transposon library was created by the laboratory of Dr. William Shafer at Emory 
University and its construction is described later in Chapter 3.  The transposon used to generate 
the library contains a kanamycin resistance cassette.  We used this library to transform 
gonococcal strain MCV515 (Table 1) by the process of liquid transformation.  Piliated gonococci 
were suspended in GCB media with Kellogg’s Supplement I, Supplement II, and 5 mM MgCl2.  
Cells were mixed with DNA from the transposon library and incubated for 30 minutes at 37°C 
with 5% CO2.  Fresh GCB/MgCl2 media was added and the mixture was incubated for an 
additional 5½ hours.  Gonococci were plated on GCB agar plates containing kanamycin (50 
g/ml) to select for transposon insertion into the gonococcal genome and incubated for 18 hours 
at 37°C with 5% CO2.   
 
III.  Screening Transposon Library Transformants 
 Single colonies from the liquid transformation of MCV515 with the transposon library 
were patched onto CDM plates containing 30% saturated human transferrin (12.5 M) (CDM-
Tf) and then onto GCB plates containing Kellogg’s Supplement I and Supplement II.  Plates 
were incubated at 37°C with 5% CO2 for 24 to 48 hours.  Samples that were unable to grow on 
the CDM-Tf plates were then passed from the GCB plate onto fresh GCB/Supplement 
I/Supplement II plates.  To ensure single colony purification, the transformants were colony 
purified by streaking 8 single colonies onto GCB/Supplement I/Supplement II plates, continuing 
this for a total of 4 passages.  Subsequently, a single colony from each of the 8 passaged samples 
was patched onto CDM-Tf plates, CDM plates containing 12 M Fe(NO3)3, and  
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Table 1.  Strains used in this study. 
 
Strain 
 
Phenotype (genotype) 
 
Source 
 
N. gonorrhoeae 
  
FA19 Wild type (130) 
FA6747 TbpA
-
 (tbpA::mTn3cat) (49) 
FA6815 TbpA
-
, TbpB
-
 (tbpB::) (5) 
FA6819 TbpB
-
 (tbpB251-708) (5) 
FA6905 TbpB
-
 (tbpB) (51) 
MCV515 L9HA TbpA (tbpA∇HA) (242) 
MCV516 L9HA TbpA, TbpB
-
 (tbpA∇HA, tbpB) (242) 
MCV650 TonB
-
 (tonB::) (77) 
MCV829 
MCV830 
MCV833 
FA19 ΔC 
L9HA TbpA, HA4 TbpB (tbpA∇HA, tbpB∇HA) 
L9HA TbpA, HA5 TbpB (tbpA∇HA, tbpB∇HA) 
L9HA TbpA, HA8 TbpB (tbpA∇HA, tbpB∇HA) 
TbpB C-lobe
-
 (tbpB-708) 
(57) 
(57) 
(57) 
This study 
FA6747 ΔC TbpA-, TbpB C-lobe- (tbpA::mTn3cat, tbpB-708) This study 
MCV515 ΔC 
Mutant 4912 
Mutant 11579 
Mutant 13614 
L9HA TbpA, TbpB C-lobe
-
 (tbpA∇HA, tbpB-708) 
L9HA TbpA, NG2117
-
 (tbpA∇HA, ng2117::km) 
L9HA TbpA, ExbD
-
 (tbpA∇HA, exbD::km) 
L9HA TbpA, ExbD
-
 (tbpA∇HA, exbD::km) 
This study 
This study 
This study 
This study 
 
E. coli 
  
TOP10 
 
 
BL21 (DE3) pLysS 
 
F
- 
mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacΧ74 recA1 araD139 Δ(ara-leu) 7697 galU 
galK rpsL (Str
R
) endA1 nupG λ- 
F- ompT hsdSB (rB-mB-) gal dcm (DE3) 
pLysS (CamR) 
Invitrogen 
 
 
Novagen 
  
29 
 
Table 2.  Plasmids used in this study. 
 
Plasmid 
 
Relevant characteristics 
 
Source 
pCR2.1 TOPO 
pET-22b(+) 
pBluescript SKII(+) 
pCR2.1 TOPO N-lobe 
 
pCR2.1 TOPO 
IGR/tbpA 
pCR2.1 TOPO C-lobe 
deletion 
pET-22b(+) N-lobe 
 
pUNCH403 
 
pUNCH750 
 
pUNCH755 
 
pUNCH768 
 
pUNCH769 
 
pUNCH770 
 
pUNCH 772 
 
pVCU521 
 
pVCU758 
Kan
R
 Amp
R 
Amp
R 
Amp
R 
pCR2.1 containing N-lobe segment of tbpB 
amplified with oVCU677 and oVCU678 
pCR2.1 containing IGR and tbpA segment amplified 
with oVCU679 and oVCU680 
pCR2.1 containing C-lobe deletion gene of ligated 
tbpB N-lobe and IGR/tbpA segments 
pET-22b(+) containing N-lobe segment of tbpB 
amplified with oVCU711 and oVCU712 
pBluescript SKII(+) containing mTn3(Cm) insertion 
in tbpA sequence 
pBluescript SKII(+) containing tbpB sequence from 
Sau3AI site to Sau3AI site 
pBluescript SKII(+) containing mTn3(Cm) 
downstream of tbpA 
pBluescript SKII(+) containing tbpB sequence from 
Sau3AI site to AccI site 
pBluescript SKII(+) containing tbpB sequence from 
Sau3AI site to AgeI site 
pBluescript SKII(+) containing tbpB sequence from 
Sau3AI site to NheI site 
pBluescript SKII(+) containing tbpB sequence from 
Sau3AI site to BspMI site 
pCR2.1 containing HA epitope insertion in loop 9 of 
tbpA 
pCR2.1 containing L9HA in tbpA and mTn3(Cm) 
downstream of tbpA 
Invitrogen 
Novagen 
Stratagene 
This study 
 
This study 
 
This study 
 
This study 
 
(49) 
 
(47) 
 
(5) 
 
(47) 
 
(47) 
 
(47) 
 
(47) 
 
(242) 
 
(Unpublished) 
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GCB/Supplement I/Supplement II plates.  Plates were incubated at 37°C with 5% CO2 for 24 to 
48 hours and any sample that was unable to grow on CDM-Tf  but able to grow on CDM- 
Fe(NO3)3 was further analyzed.   
 
IV.  Ligation-mediated PCR and DNA sequencing 
To identify the site of the transposon insertion in the gonococcal genome, we performed 
ligation-mediated polymerase chain reaction (LMPCR) as described previously (11, 149)  
(Figure 2).  The genomic DNA from transformants was digested with Sau3AI restriction enzyme 
and a linker was ligated to the ends of the DNA fragments.  The linker was formed by annealing 
LMP1 with LMP2 (Table 3).  The insertion sites were then amplified with Platinum Taq DNA 
polymerase High Fidelity (Invitrogen) using LMP1 and IR1, an outward primer to the inverted 
repeats of the transposon element (Table 3).  PCR products were cloned into TOPO pCR2.1 
vector (Invitrogen) and transformed into competent E. coli strain TOP10 (Invitrogen), following 
manufacturer’s instructions.  Plasmids were purified from overnight cultures using the Qiaquick 
spin miniprep kit (Qiagen Sciences) and sequenced by the Nucleic Acids Research Facility at 
Virginia Commonwealth University, using the provided M13 primers for the vector (Invitrogen).  
Sequences were mapped to the genome of N. gonorrhoeae using nucleotide BLAST.  Alignment 
of the sequenced products with the FA19 genome sequence from the Broad Institute database 
was completed using Vector NTi (Invitrogen).   
  
31 
 
 
 
 
 
 
 
 
Figure 2.  Schematic of Ligation-mediated PCR.  The gonococcal chromosomal DNA was 
digested with a restriction enzyme (step 1) and a linker was ligated onto the ends of the 
fragments (step 2).  The fragment containing the transposon insertion was then amplified by PCR 
using primers to the linker and the inverted repeats of the transposon (step 3).   
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Table 3.  Oligonucleotides used in this study. 
 
Oligonucleotide 
 
Sequence (5’-3’) 
 
Amplicon 
 
LMPCR oligonucleotides 
a 
LMP1 
LMP2 
IR1 
TAGCTTATTCCTCAAGGCACGAGC 
GATCGCTCGTGCCTTG 
CCGGGGACTTATCAGCCAACC 
Linker/Fwd 
Linker 
Rev 
 
C-lobe deletion oligonucleotides 
b
 
oVCU677 
oVCU678 
oVCU679 
oVCU680 
oVCU711 
oVCU712 
CTGGGCGGAGGCGGCAGTTTCG 
AAGCTTTTAGCCGCTTGAAGCCGCCG 
CCAAAAGCTTGTGAAATAAGCACGGC 
GGCGTACTTGCTGCCGTCATCAACCG 
CCCCCCCATATGCTGGGCGGAGGCGGCAGTTTCG 
CCCGGATCCTTAGCCGCTTGAAGCCGCCGGAGCA
TTGCC 
N. tbpB N-lobe Fwd 
N. tbpB N-lobe Rev 
IGR and tbpA Fwd 
IGR and tbpA Rev 
E. tbpB N-lobe Fwd 
E. tbpB N-lobe Rev 
 
 
Gene specific primers 
GC698 
 
oVCU136 
Tfbp26 
Tfbp30 
AACCTTCGTTATCGCGGCGGGTTTTCTGTTTTTTG
GCTTCTGGGTATCCAAC 
ATGAACAATCCATTGGTGAATC 
CCCAAGTAACATAGCGGTGG 
CATCAATATTTTGGGCAAAA 
tbpB C-lobe del. 
Fwd 
tbpB C-lobe del. Rev 
tbpA L9HA  Rev 
tbpA L9HA Fwd 
 
Sequences encoding novel restriction enzyme sites are bolded 
Nucleotides encoding the novel stop codon are italicized 
a
 Complementary sequences are underlined 
b
 Non-homologous nucleotides are underlined 
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V.  Generation of the TbpB C-lobe deletion 
A.  Construction of the gonococcal TbpB C-lobe deletion gene 
 Deletion of the C-lobe of TbpB was generated by DNA splicing by directed ligation 
(107) in which the DNA sequences located upstream and downstream of the gene segment to be 
deleted are amplified and then ligated together (Figure 3).  Primers were designed to the N-lobe 
segment of the tbpB gene with the forward primer, oVCU677, beginning directly after the LSAC 
lipidation sequence and the reverse primer, oVCU678, ending immediately before the start of the 
C-lobe, based on the meningococcal TbpB crystal structure (Table 3).  The reverse primer also 
contained a stop codon followed by a HindIII restriction site at the 5’ end for the ligation 
process.  Primers were also designed to the intergenic region (IGR) and beginning of tbpA, with 
the forward primer, oVCU679, starting immediately after the end of the tbpB gene which 
encodes a native HindIII site (Table 3).  The PCR products were ligated into TOPO pCR2.1 
vector and transformed into competent E. coli strain TOP10.  The transformants were screened 
for the incorporation of the PCR products into the vector by lysis followed by agarose gel 
electrophoresis and ethidium bromide (EtBr) staining.  To confirm the correct orientation of the 
PCR products, plasmids were purified using the Qiaquick spin miniprep kit, digested with 
HindIII (New England Biolabs), and subjected to agarose gel electrophoresis.  Purified plasmids 
were also sequenced at the Nucleic Acids Research Facilities of Virginia Commonwealth 
University to ensure expected gene sequence.  
To isolate the desired plasmid fragments for ligation, the vectors containing the PCR 
products were digested with the restriction enzyme HindIII (Figure 3).  This released the PCR 
product containing the N-lobe segment and the TOPO vector containing the IGR and tbpA  
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Figure 3.  Schematic of DNA splicing by directed ligation.  Primers were designed to the 
regions upstream and downstream of the tbpB C-lobe segment (step 1).  The primer to the 3’ end 
of the N-lobe sequence of tbpB encoded a restriction enzyme site for HindIII.  The 5’ end of IGR 
of the tbp operon has an intrinsic HindIII restriction enzyme site.  After PCR amplification, the 
products were cloned into pCR2.1 TOPO vector (step 2).  The plasmids were digested with 
HindIII, generating the N-lobe PCR product and vector containing the IGR and tbpA with sticky 
ends, and ligated together to create the C-lobe deletion tbpB gene (step 3).  
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portion.  These fragments were gel purified using the Qiaquick gel extraction kit (Qiagen 
Sciences), according to manufacturer’s instructions, and the TOPO vector containing the IGR 
and tbpA was treated with shrimp alkaline phosphatase (USB).  The N-lobe fragment and DNA 
ligase (Invitrogen) were added to the treated vector and incubated for 4 hours at 15°C.  
Incorporation of the N-lobe segment into the vector containing the IGR and tbpA was again 
confirmed by plasmid isolation and agarose gel electrophoresis.  The proper orientation of the N-
lobe fragment was determined by restriction enzyme digest with HindIII and EcoRI (New 
England Biolabs), separately, and agarose gel electrophoresis.   
B.  Gonococcal transformation 
 A gonococcal uptake sequence needed for transformation is present in the IGR between 
tbpB and tbpA.  The properly ligated plasmid was purified, according to manufacturer’s 
instructions (Qiagen Sciences), and linearized using KpnI (New England Biolabs).  This plasmid 
was then transformed into gonococcal wild-type FA19 strain by spot transformation.  
Approximately 10 CFU of piliated FA19 were applied to a small area of a GCB plate and the 
linearized plasmid was spotted on top of the gonococci.  Transformation mixtures were 
incubated at 37°C with 5% CO2 for 24 hours.  Subsequently, single colonies were passed onto 
additional GCB plates.  Since there was no selectable marker for this transformation, a PCR 
screen using primers GC698 and oVCU136 (Table 3) was employed to identify the 
transformants that contained the desired deletion of the TbpB C-lobe.    
To create TbpA mutations in the C-lobe deletion strain, we utilized previously made 
plasmids to transform this strain.  To generate a TbpA knockout strain, a plasmid containing a 
chloramphenicol resistance cassette in tbpA (49) (pUNCH403; Table 2) was used to transform 
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the TbpB C-lobe deletion strain by liquid transformation, detailed above.   After liquid 
transformation, gonococci were plated on GCB agar plates containing chloramphenicol (1 
g/ml) to select for allelic exchange and incubated for 24 hours at 37°C with 5% CO2.  
Transformants were streaked onto fresh GCB agar plates containing 1 g/ml of chloramphenicol 
to confirm incorporation of the chloramphenicol resistance cassette.  Inactivation of TbpA was 
confirmed using SDS-PAGE and immunodetection with anti-TbpA antibodies as described 
below.  To generate a TbpA loop 9 HA epitope insertion mutant in the C-lobe deletion 
background, we combined two previously constructed plasmids: pUNCH755 and pVCU521 
(Table 2).  pUNCH755 contains a chloramphenicol resistance cassette in the downstream region 
of tbpA (5) which was cut out of the plasmid using XbaI restriction enzyme (New England 
Biolabs).  This was then ligated into the tbpA downstream region of pVCU521 plasmid, which 
contains the HA epitope insertion in TbpA loop 9 (243), after its digestion with XbaI.  The 
ligated plasmid, pVCU758, was used for the liquid transformation of the TbpB C-deletion strain 
and selection method described above.  The HA insertion in loop 9 of TbpA was confirmed 
using PCR with primers Tfbp26 and Tfbp30 (Table 3).   
C.  Construction of plasmid to express C-lobe deletion in E. coli 
 The tbpB N-lobe segment was PCR amplified from gonococcal strain FA19 genomic 
DNA.  The forward primer, oVCU711, contained a NdeI restriction enzyme site at the 5’ end and 
additional nucleotides to aid in digestion (Table 3).  The reverse primer, oVCU712, contained a 
stop codon, BamHI restriction enzyme site, and additional nucleotides at the 5’ end (Table 3).  
This PCR product consisted of the same sequence used in the construction of the tbpB C-lobe 
deletion in N. gonorrhoeae.  The pET-22b(+) expression vector (Novagen) and the PCR product 
were digested with NdeI (New England Biolabs) and BamHI (New England Biolabs) and 
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purified using the Qiaquick PCR purification kit (Qiagen Sciences).  The PCR product and 
vector were ligated together with DNA ligase, incubating at room temperature for 1 hour.  The 
ligated vector was transformed into TOP10 E. coli cells and plasmid was purified using the 
Qiaquick spin miniprep kit.  Incorporation and orientation of the N-lobe encoding gene was 
confirmed by the digestion of the ligated plasmid with NdeI and BamHI, followed by agarose gel 
electrophoresis.  The resultant plasmid encoded the N-lobe segment of tbpB under the control of 
a T7 promoter (Table 2).  For expression of the recombinant TbpB protein, the plasmid was 
transformed into the E. coli expression strain BL21 (DE3) (Novagen) which express T7 under 
the control of the lac promoter and also carries the pLysS plasmid which produces T7 lysozyme 
to reduce basal level expression of the recombinant protein. 
D.  Recombinant protein expression 
 Cultures of E. coli (5 mls) were grown for 16 hours at 37°C and shaking at 225 rpm in 
LB broth containing 100 g/ml of ampicillin and 34 g/ml of chloramphenicol.  One milliliter of 
the starter culture was used to inoculate 100 ml of LB broth containing100 g/ml of ampicillin 
and 34 g/ml of chloramphenicol.  Cultures were shaken at 225 rpm at 37°C until they reached 
an OD600 of 0.45-0.50.  Two millimolar IPTG (isopropyl--D-thiogalactopyranoside) was added 
to induce recombinant protein expression.  One milliliter samples of the induced culture were 
taken at 0, 1, 2, and 3 hours, and centrifuged.  The pellet was solubilized with Laemmli 
solubilizing buffer, standardizing to cell density, for subsequent SDS-PAGE and 
immunodetection analysis.   
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VI.  Immunoblotting and Detection 
A.  Whole cell lysate preparation, SDS-PAGE, and protein transfer 
Gonococcal strains were grown under iron-stressed conditions as described above.  
Cultures were standardized to a constant cell number and centrifuged for 10 minutes at 13,000 
rpm.  Pellets were resuspended in Laemmli solubilizing buffer (105) and stored at -20
°
C.  Prior 
to use, -mercaptoethanol was added to 5%.  Transposon mutagenesis samples were boiled for 3 
minutes and the TbpB C-lobe deletion samples were heated for 2 minutes at 95
°
C.  All samples 
were threaded through a 28-gauge needle and subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) on 10% and 12% gels.  Proteins were 
transferred to nitrocellulose membrane (Whatman) in 20 mM Tris Base, 150 mM glycine, and 
20% methanol in a submerged transfer apparatus (Biorad) at 28 mAmps for 16 hours.   
B.  TbpA detection 
 For detection of TbpA, the nitrocellulose membranes were blocked with 5% bovine 
serum albumin (BSA) (Roche) in high-salt Tris-buffered saline (HS-TBS; 20 mM Tris base, 500 
mM NaCl) and 0.05% Tween 20 (Sigma).  Membranes were probed with polyclonal, TbpA-
specific antiserum (49) and washed with HS-TBS with 0.05% Tween 20, followed by a 
secondary goat anti-rabbit antibody conjugated to alkaline phosphatase (Biorad).  Blots were 
developed using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate (Sigma) in 
buffer containing 100 mM Tris (pH 9.5), 50 mM MgCl2, and 100 mM NaCl. 
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C.  TbpB detection 
 To detect TbpB, membranes were blocked with 5% non-fat dry milk (Biorad) in low-salt 
TBS (LS-TBS) with 0.05% Tween 20 and probed with polyclonal anti-TbpB antibody (155).  
Blots were washed with LS-TBS and 0.05% Tween 20, followed by probing with horseradish 
peroxidase (HRP) conjugated goat anti-rabbit antibody (Biorad).  Blots were developed using 
Opti-4CN substrate kit developing system (Biorad) according to manufacturer’s instructions.  
Alternatively, membranes were blocked with 5% non-fat dry milk in LS-TBS with 0.05% Tween 
20 and probed with horseradish peroxidase conjugated transferrin (HRP-Tf) (Jackson 
ImmunoResearch) as described previously (51).  HRP was detected using ECL Plus western 
blotting substrates (GE Healthcare or Pierce), according to manufacturer’s instruction, and 
reactive bands were identified by exposure to film. 
D.  TonB detection 
 For TonB detection, blots were blocked with 5% non-fat dry milk in LS-TBS with 0.05% 
Tween 20, probed with polyclonal antibody to TonB (99), and washed with LS-TBS and 0.05% 
Tween 20.  The primary antibody was detected with goat anti-mouse antibody conjugated to 
HRP (Biorad) and developed with Opti-4CN substrate developing system.   
 
VII.  Protease Accessibility Assay 
 The protease accessibility of TbpB was performed as described previously (51).  Iron-
stressed gonococci were grown in GCB liquid culture as detailed above and standardized to cell 
density.  They were treated with 2.5 g/ml trypsin (Bovine pancreatic, Sigma) for 0, 15, and 30 
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minutes.  Protease treatment was stopped by the addition of 0.6 trypsin-inhibiting units of 
aprotinin (Sigma) and the treated cells were pelleted by centrifugation.  The pellets were 
resuspended in Laemmli solubilizing buffer, followed by the immunodetection of TbpB using 
anti-TbpB antibody and HRP-Tf as specified above. 
 
VIII.  Whole-cell Binding Assays 
 Gonococcal strains were grown in liquid culture under iron-stressed conditions as 
described above.  The cultures were standardized to cell density, applied to nitrocellulose 
membrane, and allowed to dry.  Membranes were blocked with 5% non-fat dry milk in LS-TBS 
with 0.05% Tween 20.  To detect TbpB, blots were probed with polyclonal anti-TbpB antibody, 
described above, and washed with LS-TBS and 0.05% Tween 20.  Blots were then probed with 
HRP conjugated goat anti-rabbit antibody (Biorad) and developed using Opti-4CN substrate 
developing system, according to manufacturer’s instruction.  For assessment of whole-cell Tf 
binding, membranes were probed with HRP-Tf and washed with LS-TBS and 0.05% Tween 20.  
HRP was detected by the Opti-4CN system. 
 
IX.  Transferrin Utilization Assays 
 Transferrin utilization was evaluated using CDM plates supplemented with 12.5 M of 
30% saturated human transferrin.  Ferric nitrate was used as a positive control for this assay and 
added to CDM plates at a concentration of 12 M.  Strains were streaked onto plates and 
incubated at 37°C in a 5% CO2 atmosphere for 24 to 48 hours. 
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X.  Saturation of Human Transferrin 
 Apo human transferrin (Sigma) was resuspended in ferration buffer, pH 8.4 (100 mM 
Tris, 150 mM NaCl, 20 mM NaHCO3) to a concentration of 10 mg/ml.  Iron solution, pH 8.6 
(100 mM NaCitrate, 100 mM NaHCO3, 5mM FeCl3) was added to achieve the saturation 
percentages of 5, 10, 20, 30 and 50, and incubated for one hour at room temperature.  The 
ferrated transferrin solution was dialyzed at room temperature for 4 hours in a 200-fold volume 
of dialysis buffer, pH 7.4 (40 mM Tris, 150 mM NaCl, 20 mM NaHCO3).  The buffer was 
changed and dialysis was allowed to proceed overnight at 4°C.  These differentially saturated 
transferrin samples were then used in transferrin utilization assays as described above. 
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CHAPTER 3:  Identification of the TbpB Transport Mechanism through 
Transposon Mutagenesis 
 
I.  Introduction 
 The outer membrane of Gram-negative bacteria is comprised of proteins, phospholipids, 
and LPS or LOS.  There are two types of proteins in the outer membrane: lipoproteins that are 
anchored to the membrane with a lipid tail and integral proteins that contain membrane-spanning 
regions.  These proteins, along with some periplasmic and inner membrane proteins, are 
transported across the inner membrane through the general secretory pathway consisting of the 
multi-subunit Sec machinery.  The Sec translocase is responsible for the transport of unfolded 
proteins into the periplasm, which occurs without compromising the general permeability of the 
membrane (133).  An N-terminal signal sequence targets proteins to the Sec system and is 
removed after translocation.  Distinct mechanisms exist for the localization of the proteins to 
their final destination in the cell wall.  These mechanisms have been extensively studied in E. 
coli but remain largely uncharacterized in other Gram-negative bacteria. 
First, there are two types of N-terminal signal sequences, signal I and signal II.  Signal I 
releases the protein into the periplasm where it can be secreted or inserted into the outer 
membrane, most likely with the aid of a periplasmic chaperone (185).  Signal II causes the 
protein to be lipidated and anchored in the outer leaflet of the inner membrane (157).  This signal 
sequence contains a distinct region, known as the lipobox, that acts as a recognition site for 
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cleavage and lipid modification.  The consensus sequence for about three-fourths of all 
lipoproteins in bacteria is Leu-(Ala, Ser)-(Gly, Ala)-Cys (83).  The modification reaction 
involves three steps: the addition of a diacylglycerol group to the sulfhydryl group of the 
cysteine residue, cleavage of the signal peptide, and aminoacylation of the cysteine (178).  The 
mature lipoproteins formed through this process have a lipid-modified cysteine as the first 
residue at the N-terminus. 
Following the addition of a lipid moiety to the protein, sorting to the inner or outer 
membrane occurs.  This signal consists of the amino acids directly adjacent to the lipidated 
cysteine.  The inner membrane retention signal is an aspartate at position 2 of the protein (239).  
However, it has also been demonstrated that the residue at position 3 can affect the localization 
of a lipoprotein (67).  Proteins with this signal are retained on the periplasmic side of the inner 
membrane while proteins lacking this signal are transported to the outer membrane.  Since lipid 
modification occurs at the inner membrane, proteins are involved in binding to the hydrophobic 
lipid tail of the lipoprotein and carrying it across the hydrophilic environment of the periplasm. 
Bacterial lipoproteins have been shown to be involved in a variety of processes including 
nutrient uptake, signal transduction, adhesion, transport, and antibiotic resistance.  E. coli has 
over 90 lipoprotein species, most of which are localized in the inner leaflet of the outer 
membrane (141).  The transportation of these lipoproteins is accomplished by the lipoprotein 
localization (Lol) machinery, comprised of the inner membrane protein complex LolCDE, the 
periplasmic chaperone LolA, and the outer membrane receptor LolB (Figure 2) (204, 205).  LolC 
and LolE are integral membrane proteins that form a complex with LolD, an ATPase, to act as an 
ATP-binding cassette (ABC) transporter (238).  This complex is responsible for recognizing 
lipoproteins destined for the outer membrane and releasing them from the inner membrane 
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Figure 2.  Schematic of the Lol system in E. coli.  The Sec system recognizes the N-terminal 
signal sequence of lipoproteins and translocates them across the inner membrane (IM) in an 
unfolded state.  In the periplasm (PP), the signal sequence is cleaved, the lipid moiety is added, 
and the protein is folded and inserted into the periplasmic side of the IM.  Signal I proteins are 
retained in the inner membrane and signal II proteins are recognized by the LolCDE complex.  
Lipoproteins are released from the inner membrane and shuttled across the periplasm to the outer 
membrane (OM) by LolA.  LolA transfers the lipoproteins to the outer membrane receptor LolB, 
which inserts them into the inner leaflet of the OM. 
 
 
\ 
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to the periplasmic chaperone LolA (238).  LolA, a lipoprotein-specific molecular chaperone, 
forms a complex with a lipoprotein and shuttles it across the periplasm to the outer membrane 
(123).  Here, LolA transfers the lipoprotein to LolB, the outer membrane receptor that is 
anchored to the outer membrane by its own lipid moiety (124).  This transfer is energy 
independent and presumably driven by the difference in affinity for lipoproteins between the two 
proteins (124).  LolB then inserts the lipoprotein into the inner leaflet of the outer membrane 
through an unknown mechanism (141).  Deletion of any of these proteins in E. coli is lethal (142, 
199, 200). 
The Lol system is well conserved in Gram-negative bacteria and Neisseria do have 
LolABCD homologs (103, 201).  Although there is no LolE homolog, LolC and LolE exhibit 
considerable sequence similarity and LolC may function as a homodimer (23).  However, the 
contribution of the Lol system in lipoprotein transport in Neisseria has not been confirmed (214), 
indicating different machinery may be responsible or a different mechanism of export exists.  
Neither of these options has been identified and the method of lipoprotein transport to the outer 
membrane remains unknown.  Also, all known lipoproteins in E. coli face the periplasm (24) 
while other mircoorganisms, such as Klebsiella (54), Bordetella (52), and Borrelia (74), also 
have surface-exposed lipoproteins.  Neisseria produce lipoproteins on the cell surface with TbpB 
being fully surface exposed and anchored to the outer membrane only by its lipid moiety (57).  
The mechanism of translocation of these lipoproteins across the outer membrane to be localized 
in the outer leaflet is also unknown. 
 Neisserial TbpB has a lipobox sequence of LSAC with a leucine at the +2 position, 
suggesting that it might be a substrate for an export process similar to the Lol system.  
Additionally, transport to the outer membrane may be dependent on sequence-specific signals 
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within the protein.  Previous studies in our lab, done by Amanda DeRocco and Karen Ostberg, 
analyzed the role of lipidation in the localization of TbpB to the outer membrane and 
demonstrated that it is necessary for transport and surface exposure of the protein.  Amanda 
DeRocco generated a TbpB mutant where the lipoprotein signal II sequence (LSAC) was 
changed to a signal I sequence (LAAA).  She showed that although the non-lipidated protein was 
able to bind transferrin by western blot, it did not bind transferrin at the cell surface, indicating 
that it was not surface exposed (unpublished data).  Karen Ostberg confirmed the LSAC TbpB 
mutant was not lipidated through palmitic acid labeling and it was actually secreted (unpublished 
data).  These data indicate that without the lipid moiety, TbpB still enters the periplasm as a fully 
functional protein but is not associated with the cell surface and is secreted into the extracellular 
milieu.  Although the non-lipidated TbpB protein is secreted, this does not rule out the possibility 
of proteinaceous machinery being involved in the transport of lipidated proteins.  Additionally, 
translocation across the outer membrane to be anchored in the outer leaflet is expected to require 
a large pore formed by a protein or protein complex. 
In this study, we sought to identify the mechanism of TbpB transport to the outer 
membrane and its localization to the outer leaflet of the outer membrane in N. gonorrhoeae.  We 
screened mutants generated using a transposon library, created by the laboratory of William 
Shafer, for defects in human transferrin utilization.  This library had been previously used to 
identify gonococcal genes involved in the resistance to antimicrobial agents of the innate host 
defense (11).  We isolated three potential TbpB export deficient mutants and identified the 
location of the transposon insertions in the genome of these mutants through LMPCR and DNA 
sequencing.  Finally, we analyzed the surface exposure of TbpB in these mutants using protease 
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accessibility assays.  If the export of TbpB was being affected by the transposon insertion, TbpB 
would not be on the cell surface and the surface exposure of TbpB would be undetectable.   
 
II.  Results 
A.  Screening of transposon library revealed multiple potential TbpB export mutants 
 The transposon library was constructed by carrying out saturated mutagenesis in the 
chromosomal DNA of gonococcal strain F62 using a transposon containing a kanamycin 
resistance cassette with flanking Himar1 inverted repeats (11).   The DNA was reintroduced into 
the strain by natural transformation, and the chromosomal DNA from 10,000 colonies was 
isolated to create the library (11).  In order to screen for defects in TbpB transport to the outer 
membrane, we utilized a previously created mutant, MCV515, that has a hemaglutinin (HA) 
epitope in the loop 9 (L9) of TbpA.  This mutant binds transferrin with wild-type affinity but can 
utilize transferrin only in the presence of TbpB (243), which must be on the cell surface 
(unpublished data).  Therefore, if TbpB is not being transported to the cell surface, then the 
gonococci will not be able to utilize transferrin as an iron source in this background strain.  This 
can be used to screen for potential TbpB export deficient transformants.  The transposon library 
was transformed into the MCV515 background and the growth phenotypes of the generated 
mutants were examined on CDM-Tf plates.  Any mutants that were unable to grow on transferrin 
were then colony purified and retested on CDM-Tf and CDM-Fe(NO3)3 plates.  The use of 
CDM-Fe(NO3)3 was to determine if the mutation caused a CDM related growth defect or if it 
was specific to the use of transferrin.  Through this screening, several potential TbpB export 
deficient mutants were identified:  mutants 4912, 11579, and 13614.  Their growth phenotypes 
(Tf-negative and Fe(NO3)3–positive) were confirmed on CDM plates (Figure 5; mutant 13614  
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Figure 5.  Growth phenotype of potential TbpB export deficient mutants on CDM plates.  
Potential TbpB export deficient gonococcal mutants 4912 (A and B), 11579 (C and D), and 
13614 (data not shown) were plated onto CDM medium containing either 30% saturated Tf (A 
and C) or Fe(NO3)3 (B and D) as the sole iron source.  MCV515 and MCV516 serve as the 
positive and negative control strains, respectively.    
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data not shown).  To date, we have screened more than 14,000 mutants using this form of 
mutagenesis and screening. 
B.  Identification of the transposon insertion sites 
 The ability of N. gonorrhoeae to utilize transferrin as an iron source is dependent on the 
transferrin iron acquisition system described earlier.  This system includes two outer membrane 
proteins, TbpA and TbpB, and an energy transduction system, TonB-ExbB-ExbD.  Thus, 
disruption of their function could account for the Tf-negative and Fe(NO3)3–positive growth 
phenotype.  To ensure that the transposon insertion was not affecting their expression, we used 
western blot analysis to examine the protein expression of TbpA, TbpB, and TonB in the 
potential TbpB export mutants.  Mutant 4912 showed wild-type expression of all three proteins 
(Figure 6), indicating that these proteins were not affected by the mutation.  We then used 
ligation-mediated PCR (LMPCR) to amplify the gonococcal chromosomal DNA flanking the 
transposon insertion.  The PCR product was cloned into a TOPO vector and sequenced to 
determine the location of the insert in the genome.  The transposon in mutant 4912 mapped to 
gene NG2117, a possible membrane-spanning domain (MSD) protein in an ABC transport 
system.  This is promising since an ABC transport system is an important part of the Lol system 
in E. coli.   
  Mutants 11579 (data not shown) and 13614 (Figure 7) exhibited similar protein 
expression profiles with wild-type expression levels and protein sizes for TbpA and TbpB.  
However, detection of TonB in these mutants showed a protein with a higher molecular weight 
and slightly lower level of expression than wild-type.  This indicates that the transposon 
insertions in mutants 11579 and 13614 were affecting the expression, and most likely, function  
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Figure 6.  Protein Expression of Tbps and TonB in mutant 4912.  Whole cell lysates of iron-
stressed gonococci were subjected to SDS-PAGE and transferred to nitrocellulose.  Blots were 
probed with anti-TbpA (top panel), anti-TbpB (middle panel), or anti-TonB (bottom panel) 
polyclonal antibodies.  FA19 and MCV515 serve as the wild-type and parent strain controls, 
respectively.  FA6747 is a TbpA
-
 control, FA6905 is a TbpB
-
 control, and MCV650 is a TonB
- 
control. 
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Figure 7.  Protein Expression of Tbps and TonB in mutant 13614.  Whole cell lysates of 
iron-stressed gonococci were subjected to SDS-PAGE and transferred to nitrocellulose.  Blots 
were probed with anti-TbpA (top panel), anti-TbpB (middle panel), or anti-TonB (bottom panel) 
polyclonal antibodies.  FA19 and MCV515 serve as the wild-type and parent strain controls, 
respectively.  FA6747 is a TbpA
-
 control, FA6905 is a TbpB
-
 control, and MCV650 is a TonB
- 
control. 
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of the TonB protein and/or TonB-ExbB-ExbD complex.  LMPCR and DNA sequencing revealed 
that the transposon inserted into the ExbD protein.  Therefore, the insertion was affecting the 
proper function of the TonB-ExbB-ExbD complex and this, rather than a TbpB export defect, is 
responsible for the growth phenotype seen in these mutants.   
C.  Characterization of the surface exposure of TbpB in Mutant 4912 
 If lipoprotein export to the outer membrane or translocation to the outer leaflet was being 
disrupted through the insertion of a transposon, then TbpB would remain either in the inner 
membrane or in the inner leaflet of the outer membrane.  Therefore, the surface accessibility of 
TbpB would be affected and we would not be able to detect TbpB on the cell surface.  We used 
two different methods to determine surface exposure of the protein:  protease accessibility and 
whole-cell binding assays.  It has been previously shown that surface exposed TbpB is 
susceptible to trypsin degradation (51) and periplasmic TbpB is not susceptible to degradation 
(unpublished data).  We treated whole cells with trypsin for various lengths of time and detected 
TbpB protein products through western blot analysis using anti-TbpB antibody (Figure 8).  TbpB 
detection showed susceptibility to trypsin digestion, demonstrating a protein banding pattern 
similar to the wild-type strain (Figure 8).  This degradation suggests that TbpB in mutant 4912 is 
accessible on the cell surface and still getting exported to the outer membrane and oriented to 
extracellular surface in mutant 4912 
D.  Mutant 4912 is a mixed population  
 After determining that mutant 4912 produces surface exposed TbpB, we retested the 
growth phenotype on CDM plates.  Samples of mutant 4912 displayed multiple growth 
phenotypes with growth on transferrin but not Fe(NO3)3, no growth on either transferrin or   
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Figure 8.  Protease accessibility of TbpB in Mutant 4912.  Iron-stressed gonococci were 
treated with trypsin for 0, 15, and 30 minutes, followed by the addition of aprotinin.  Whole cell 
lysates were subjected to SDS-PAGE, transferred to nitrocellulose, and probed with polyclonal 
anti-TbpB serum.  Untreated samples are labeled with U and treated samples are labeled with 
their respective times. Arrows indicate trypsin-degraded products and molecular weight markers 
are indicated on the right with strain names listed above.  FA19 and MCV515 serve as the wild-
type and parental controls, respectively.  
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Fe(NO3)3, and growth on both transferrin and Fe(NO3)3 plates (Figure 9).  None of the samples 
exhibited the expected phenotype for a TbpB export deficient mutant in this screen.  This 
inconsistent growth phenotype indicated the original mutant that was thought to be colony 
purified was actually a mixed population with different genotypes.  A sample of mutant 4912 
that demonstrated the original growth phenotype could not be isolated from the samples.  
Therefore, no conclusions can be made about the involvement of the NG2117 gene in the 
transport of TbpB and other lipoproteins to the outer membrane. 
 
III.  Discussion 
In addition to acting as a selective barrier, the outer membrane holds many proteins that 
serve a diverse array of functions, including nutrient uptake, enzymatic activities, and adhesion 
and invasion.   These proteins are essential for survival and localization to the correct 
compartment of the cell envelope is necessary for their proper function.  Although the Lol 
system is well conserved among Gram-negative bacteria, differences in the protein apparatus and 
signal sequences do exist (143).  No functional Lol system or any other lipoprotein transport 
system has been identified in N. gonorrhoeae.  Additionally, gonococci produce surface exposed 
lipoproteins, such as TbpB, that are anchored in the outer leaflet of the outer membrane, unlike 
E. coli.  However, no system of lipoprotein transport across the outer membrane has been 
elucidated in N. gonorrhoeae or any other bacteria.  We sought to identify the mechanism of 
lipoprotein export to the outer membrane and orientation in the outer leaflet by exploiting the 
transferrin-iron acquisition system N. gonorrhoeae. 
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Figure 9.  Growth phenotype of mutant 4912 is inconsistent.  Multiple samples of potential 
TbpB export deficient mutant 4912 were plated on CDM medium with either 30% saturated Tf 
or Fe(NO3)3 as the sole iron source.  All samples are individual isolates of mutant 4912 and 
labeled with numbers 1 through 8.  MCV515 and MCV516 serve as the positive and negative 
control strains, respectively.    
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To accomplish this, we used a transposon library, generated by the laboratory of William 
Shafer at Emory University, to generate mutants in the gonococcal strain MCV515.  This 
background is completely dependent on the presence of TbpB at the cell surface to utilize 
transferrin as an iron source.  Therefore, if TbpB export to the cell surface is being interrupted by 
the transposon insertion, the gonococci will not be able to grow on CDM-transferrin plates, 
which serves as the screen when looking for potential mutants.  This mutagenesis and screening 
process appeared promising since the library had been previously used to identify important 
genes involved in serum resistance (11) and the screen seemed straigTforward.   
Using this method, we isolated three promising mutants that were unable to utilize 
transferrin as an iron source (Figure 5).  We performed western blot analysis of TbpA, TbpB, 
and TonB to ensure that none of the major proteins involved in the uptake of iron from 
transferrin were affected by the transposon insertion.  Unfortunately, two of these, mutants 
11579 and 13614, had altered TonB protein size and expression (Figure 7) caused by transposon 
insertion in the ExbD gene.  The ExbD protein is part of the TonB-ExbB-ExbD energy 
transduction system necessary for TonB dependent transport.  It had been shown previously that 
the utilization of iron bound to transferrin, lactoferrin, and hemoglobin in Neisseria is dependent 
on the TonB system (15, 194).  Since the internalization of iron through the gonococcal 
transferrin receptors is TonB dependent, the transposon insertion in ExbD and disruption of this 
system is responsible for the growth phenotype.  Therefore, the transport of TbpB to the cell 
surface is not being affected in these mutants.  However, this information is vital to our study 
since it proves that the method of mutagenesis and screening can successfully identify 
gonococcal isolates that are incapable of using transferrin as an iron source. These data also 
suggest that ExbD, and possibly ExbB, has a significant role in the processing and expression of 
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TonB.  To our knowledge, this is the first data to show a role of ExbD in the protein expression 
on TonB in Neisseria. 
 The other mutant obtained through this mutagenesis and screening process, mutant 4912, 
had wild-type expression of the TbpA, TbpB, and TonB proteins (Figure 6), indicating that none 
of these proteins were affected by the transposon insertion.  Therefore, the growth phenotype 
was due to the disruption of an undetermined gene which, though LMPCR and DNA sequencing, 
was identified as gene NG2117.  This gene encodes a possible membrane-spanning domain 
protein in an ABC transport system.  In the E. coli Lol system, LolC and LolE act as the 
membrane spanning domains of the ABC transport with LolD acting as the ATP-binding domain 
(204, 205).  It is very likely that the neisserial lipoprotein transport system has a similar structure 
and organization.  Based on this, the NG2117 gene looked very promising as a component of the 
lipoprotein transport machinery in Neisseria. 
However, protease accessibility assays showed that TbpB was surface accessible and 
present at the cell surface in mutant 4912 (Figure 8).  These data imply that TbpB is surface 
exposed and the export of lipoproteins to the outer leaflet of the outer membrane is functional.  
Therefore, the ABC transport system MSD encoded by gene NG2117 may not be involved in the 
transport of TbpB to the cell surface.  Upon reexamination of the mutant’s growth phenotype, we 
found that ability to utilize transferrin and Fe(NO3)3 as iron sources varied with different samples 
(Figure 9), indicating that mutant 4912 is a mixed population.  This denotes that various 
genotypes are present in the mutant 4912 population, which includes other mutations in addition 
to the NG2117 mutation.  Therefore, the samples used for the protease accessibility assay 
contained multiple genotypes and phenotypes.  This confounds the results of this assay since a 
TbpB export deficient phenotype may be obscured by the presence of gonococci that are capable 
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of TbpB export.  An isogenic population is needed for the evaluation of NG2117 participation in 
TbpB localization.  Thus, no conclusions can be made about the possible function of NG2117 in 
the transport of lipoproteins to the outer membrane. 
To date, we have screened over 14,000 mutants using the transposon library and 
transferrin utilization screening method.  With the number of mutants screened and the size of 
the transposon library, it seems that we have exhausted this approach of identifying the export 
mechanism of lipoproteins in N. gonorrhoeae.  Additionally, we have isolated duplicates of 
mutants, further confirming that we have reached the system’s capacity.  Two rationales exist as 
to the failure of this method.  First, since the transposon library was made from a collection of 
10,000 colonies, it is limited in the number of mutations it contains and the mutations we were 
screening for may not be included.  Second, disruption of the lipoprotein export system may be 
lethal in the gonococci and deletions of the proteins involved cannot be obtained.  This is a 
possibility since all of the Lol proteins in E. coli are essential for growth (142, 199, 200).  The 
transport mechanisms of neisserial lipoproteins to the outer membrane and orientation to the cell 
surface remain unknown. 
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Chapter 4:  Characterization of C-lobe Deletion of TbpB 
 
I.  Introduction 
 Iron is an essential nutrient for most organisms and is required for bacterial growth.  
Therefore, most pathogens have evolved several mechanisms of obtaining iron in the human 
host, which is seen as a virulence factor.  One method is the utilization of host iron-binding 
proteins, such as transferrin, through bacterial receptor-mediated interactions.  Members of the 
Neisseriaceae, Pastuerellaceae, and Moraxellaceae families are capable of using transferrin as 
an iron source and their transferrin iron acquisition systems have been studied extensively.  The 
transferrin receptor complex is vital for bacterial infection of the natural host (10, 50), indicating 
the importance of transferrin iron acquisition. 
These transferrin iron uptake systems consist of two distinct outer membrane proteins: 
transferrin binding protein (Tbp) A and B.  Both proteins specifically and independently bind 
transferrin but only TbpA is necessary for the use of transferrin-bound iron (51).  TbpA is a 
TonB-dependent transporter that is responsible for translocating iron across the outer membrane, 
into the cell (49).  TbpB is a bilobed, surface exposed lipoprotein whose precise role in the 
utilization of transferrin as an iron source has not yet been defined.  However, it makes the 
internalization of transferrin-bound iron more efficient by distinguishing between apo- and holo-
transferrin (26, 51).  This enhances the interaction between the transferrin receptor complex and 
the ferrated transferrin molecule, which is the optimum ligand for the iron transport system.   
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 Transferrin is a monomeric, serum glycoprotein that binds iron for sequestering and 
transport.  It has two homologous domains, the N-lobe and C-lobe, each containing an iron-
binding site (117).  This bilobed structure resulted from an early gene duplication with 
independent evolution of the two domains subsequently (233).  Although iron preferentially 
binds the N-lobe (235), it has been demonstrated that only the C-lobe of human transferrin is 
capable of binding to the Tbps (3, 163).  The crystal structure of the meningococcal Tbps in 
complex with iron-bound human transferrin also showed both Tbps interacting tightly with the 
C-lobe, having unique, non-overlapping binding sites (146).  However, the C-lobe alone was 
unable to support the growth of iron-limited cultures of N. meningitidis, suggesting that both 
lobes are necessary for efficient iron release from transferrin (2). 
It has long been hypothesized that TbpB is bilobed, similar to transferrin, based on 
internal sequence redundancy (125) and regions of identity between the N-terminal and C-
terminal halves (164).  These conserved regions of TbpB are interspersed within hypervariable 
domains (167) and are also observed in other species, such as M. catarrhalis, H. influenzae, 
Pasteurella haemolytica, and Actinobacillus pleuropneumoniae (164).  The bilobed structure of 
TbpB was recently confirmed by the crystal structure of the protein from both A. 
pleuropneumoniae (132) and N. meningitidis (32, 146).  The crystal structures also revealed the 
structural similarity between the lobes with each lobe subdivided into an eight-strand -barrel 
domain and an adjacent four-strand handle domain (32, 132, 146).  Due to the similar bilobed 
structure of transferrin and TbpB, it has been hypothesized that TbpB evolved in parallel with 
transferrin to adapt to its ligand (125). 
 The contribution of the two lobes to the function of TbpB has been well studied but 
remains controversial.  In N. meningitidis, both lobes have been attributed with transferrin 
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binding.  Although initial studies showed only the N-lobe is involved in transferrin binding 
(213), subsequent studies have also implicated the C-lobe (162, 164).  These studies 
demonstrated that both the N-terminal and C-terminal halves of TbpB could bind independently 
to human transferrin, but the N-lobe binds with higher affinity than the C-lobe (162, 164).  It has 
been speculated that the transferrin and TbpB interaction occurs primarily between the Tf C-lobe 
and TbpB N-lobe but an additional low-affinity interaction may also occur between the Tf N-
lobe and TbpB C-lobe (162, 164).  However, all of these studies used recombinant TbpB proteins 
with many of them using purified fusion proteins. 
Cornelissen et al. used the ability of TbpB to bind transferrin on a ligand-binding western 
blot to define a minimal domain necessary for transferrin binding by gonococcal TbpB (47).  
They made progressive deletions from the C-terminal end of TbpB and cloned them into E. coli 
to analyze the role of several conserved regions in transferrin binding.  All of the deletion 
constructs were expressed by E. coli but only a deletion from the N-terminal and the largest C-
terminal deletion, which included a conserved region in the end of the N-terminal half, were 
unable to bind transferrin.  These results suggested that only the conserved regions in the N-
terminal half of TbpB are involved in transferrin binding.  Again, this study used recombinant 
proteins, providing insight into in vitro transferrin binding of TbpB. 
 However, in vivo studies by DeRocco and Cornelissen using intact gonococcal cells 
demonstrated that both the N- and C-lobes were involved in transferrin binding at the cell surface 
and utilization of transferrin as an iron source (57).  Hemagglutinin (HA) epitopes were inserted 
into 9 locations within TbpB, 5 in the N-lobe and 4 in the C-lobe.  Through ligand-binding 
western blot analysis, they demonstrated that only HA insertions 3, 4, and 5, which were all 
located within the N-lobe, diminished transferrin binding, consistent with the previous study.  
70 
 
However, whole-cell binding assays revealed that HA insertions 4 and 5, as well as 8, decrease 
transferrin binding at the gonococcal cell surface.  HA8 insertion is in the C-lobe and in 
combination with either HA4 or HA5 insertions, transferrin binding was completely abolished at 
the cell surface.  Transferrin utilization and iron internalization was also impaired in these three 
individual HA insertions, determined by growth assays on CDM-transferrin and iron uptake 
assays using radiolabeled iron, respectively.  Taken together, these data suggest that although 
only the N-lobe is required for in vitro transferrin binding using isolated protein, both lobes are 
involved in transferrin binding and utilization in whole, intact gonococcal cells, referred to as in 
vivo in this study. 
To further delineate the role of the C-lobe in transferrin binding and iron stripping, we 
generated a C-lobe deletion mutant of TbpB through DNA splicing by directed ligation (107).  
This mutant included the full length, wild-type N-lobe and the linker region connecting the two 
lobes.  We used this mutant to characterize the expression of the single TbpB lobe in both N. 
gonorrhoeae and E. coli.  We also analyzed the ability of the N-lobe alone to bind transferrin by 
ligand-binding western blot analysis and on the cell surface through whole-cell binding assays.  
Finally, we evaluated transferrin utilization in the mutant by plating it on CDM-transferrin 
medium.  Since previous studies in both N. meningitidis and N. gonorrhoeae demonstrated that 
in vitro transferrin binding occurs primarily in the N-lobe, we hypothesized the TbpB C-lobe 
deletion protein would still be able to bind transferrin by ligand-binding western blot.  However, 
we hypothesized that deletion of the C-lobe would hinder the function of TbpB in the 
gonococcus since both lobes were shown to be involved in transferrin binding and utilization at 
the cell surface (57). 
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II.  Results 
A.  Deletion of the C-lobe causes degradation of TbpB 
 Based on the TbpB gonococcal sequence and gonococcal homology model of the 
meningococcal TbpB crystal structure (146), we constructed a full and precise deletion of the C-
lobe of gonococcal TbpB.  The deletion gene was designed to end at the exact beginning of the 
C-lobe so it included the full N-lobe as well as the full linker region connecting the lobes.  The 
C-lobe deletion gene was transformed into wild-type (FA19), insertional inactivated TbpA 
(FA6747), and TbpB-dependent for Tf utilization (MCV515) gonococcal background strains to 
be characterized.  Expression of the TbpB C-lobe deletion protein was examined using western 
blot analysis, probing with anti-TbpB antibody.  These gonococcal liquid cultures grown under 
iron-stressed conditions for 4 hours expressed no detectable TbpB C-lobe deletion protein 
(Figure 10).  Additionally, no TbpB protein was detected in strains grown on GCB supplemented 
with DFO plates to induce iron-stressed conditions (Figure 11).  However, breakdown products 
of TbpB were able to be detected indicating that some protein was being produced.  Most of the 
antibody reactive material in the C-lobe deletion strains was located at the bottom of the blot as 
degraded product.  This suggested that the TbpB C-lobe deletion protein was being produced but 
degraded in N. gonorrhoeae.   
  Since the previous work to identify the regions of gonococcal TbpB involved in 
transferrin binding was done using recombinant proteins epressed in E. coli, we cloned the same 
tbpB sequence from the C-lobe deletion gene into pET-22b(+) expression vector and transformed 
it into BL21(pLysS) E. coli cells.  Similar to the constructs made by Cornelissen et al., this 
cloned gene did not contain the native promoter or lipidation signal.  Protein expression of the C- 
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Figure 10.  Degradation of TbpB in gonococcal C-lobe deletion strains grown in liquid 
cultures.  Whole cell lysates of iron-stressed gonococci grown in liquid culture for 4 hours were 
subjected to SDS-PAGE and transferred to nitrocellulose.  Blots were probed with anti-TbpB 
polyclonal antibody.  FA19, MCV515, and FA6747 serve as the wild-type TbpB and parent 
strain controls.  Deletion of the TbpB C-lobe in these backgrounds is indicated with C.  
FA6815 and FA6819 serve as controls for deletions in the tbpB gene.  Molecular weight markers 
are indicated on the right. 
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Figure 11.  Degradation of TbpB in gonococcal C-lobe deletion strains grown on plates.  
Whole cell lysates of iron-stressed gonococci grown on GCB agar plates with DFO were 
subjected to SDS-PAGE and transferred to nitrocellulose.  Blots were probed with anti-TbpB 
polyclonal antibody.  FA19, MCV515, and FA6747 serve as the wild-type TbpB and parent 
strain controls.  Deletion of the TbpB C-lobe in these backgrounds is indicated with C.  
FA6815 and FA6819 serve as controls for deletions in the tbpB gene.  Molecular weight markers 
are indicated on the right. 
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lobe deletion in E. coli was induced using IPTG and whole cell lysates taken at one-hour 
timepoints were analyzed by western blot analysis, probing with anti-TbpB antibodies.  
Interestingly, the TbpB C-lobe deletion protein was detected in E. coli at the expected molecular 
weight (Figure 12).   However, the protein was detected at a very low expression level only at the 
one hour induced timepoint (Figure 12).  The protein band disappeared after two and three hours 
of induction (Figure 12), indicating that the protein is also being degraded in E. coli.  The 
previously made constructs were expressed at normal detectable levels in E. coli, suggesting that 
something specific about this C-lobe deletion construct caused the protein to be degraded. 
 After detection at the one hour timepoint in E. coli, we grew iron-stressed cultures of the 
C-lobe deletion gonococcal strain in the wild-type FA19 background taking one-hour timepoints.  
We again analyzed the protein expression of the C-lobe deletion of TbpB by western blot 
analysis but used a more sensitive anti-TbpB antibody.  With this, we were able to detect a band 
that increased over time with the increase of iron starvation around the same molecular weight as 
the C-lobe deletion in E. coli (Figure 13).  We judged this to be the TbpB C-lobe deletion protein 
in N. gonorrhoeae which was detectable with the more sensitive antibody but still expressed at a 
much lower level than wild-type TbpB.  This further implies that the C-lobe deletion protein of 
TbpB is being degraded. 
B.  TbpB N-lobe is unable to bind transferrin in vitro and in vivo 
 The ability of TbpB to bind transferrin is retained after denaturation and SDS-PAGE 
analysis, and HRP-transferrin can be used to detect transferrin binding on a ligand-binding 
western blot.  We used this characteristic to determine the transferrin binding capability of the 
TbpB N-lobe protein that was made by the deletion of the C-lobe in N. gonorrhoeae.  The  
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Figure 12.  Degradation of induced TbpB N-lobe construct in E. coli.  Whole cell lysates 
were taken at one-hour timepoints of IPTG-induced E. coli containing the TbpB N-lobe construct 
in pET-22b(+) expression vector.  Lysates were subjected to SDS-PAGE, transferred to 
nitrocellulose, and probed with anti-TbpB polyclonal antibody.  Samples of the induction of 
TbpB N-lobe construct in E. coli are indicated by their timepoints.  FA19 and FA19 C are the 
TbpB wild-type and C-lobe deletion gonococcal control strains, respectively.  FA6819 serves as 
a control for deletions in the gonococcal tbpB gene and pUNCH750 serves as a control for the 
expression of tbpB gene deletions in an expression vector in E. coli.  Molecular weight markers 
are indicated on the right and the arrow indicates the TbpB C-lobe deletion. 
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Figure 13.  Detection of gonococcal TbpB C-lobe deletion over time.  The TbpB C-lobe 
deletion gonococcal strain (FA19 C) was grown under iron-stressed conditions in liquid 
cultures.  Whole cell lysates of the TbpB C-lobe deletion gonococci were taken every hour for 4 
hours.  Lysates were subjected to SDS-PAGE, transferred to nitrocellulose, and probed with anti-
TbpB polyclonal antibody.  Samples of FA19 C are indicated by their respective timepoints.  
FA19 serves as the wild-type TbpB and parent strain control.  E. coli N-lobe serves as the TbpB 
C-lobe deletion control for size comparison and pUNCH750 serves as a control for the 
expression of tbpB gene deletions in an expression vector in E. coli.  Molecular weight markers 
are indicated on the right and the arrow indicates the TbpB C-lobe deletion. 
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western blot detecting Tf binding revealed that the N-lobe alone was incapable of binding 
transferrin in any gonococcal background (Figure 14).  Western blot analysis of the one hour 
timepoints of the TbpB C-lobe deletion in wild-type FA19 background also showed that the N-
lobe protein was not able to bind transferrin at any time of iron-stress (Figure 15A).  A longer 
exposure revealed that the protein might be capable of minimal transferrin binding (Figure 15B).  
However, these data suggested that deletion of the C-lobe renders the remaining N-lobe TbpB 
protein unable to bind transferrin at detectable levels in vitro and nonfunctional in the 
gonococcus. 
 The transferrin binding capability of the gonococcal TbpB C-lobe deletion protein 
created in this study was also examined in E. coli strain containing the C-lobe deletion construct.  
To do so, whole cell lysate of the one hour induced sample was run on an SDS-PAGE gel in 
parallel with previously made TbpB constructs (pUNCH plasmids; Table 1) generated by James 
E. Anderson from the Cornelissen et al. studies identifying the minimal transferrin binding 
domain of TbpB (47).   They used intrinsic restriction enzyme sites in the gonococcal tbpB 
sequence to make progressive deletions of from the C-terminal end.  These constructs do not 
contain the native promoter or N-terminal signal sequence and vary in their ability to bind 
transferrin.  We again used anti-TbpB antibody to detect the expression of the TbpB constructs 
and HRP-transferrin to analyze their transferrin binding capabilities.  TbpB expression was 
detected in all of the whole cell lysates (Figure 16A) with transferrin binding only eliminated in 
the pUNCH770 plasmid and C-lobe deletion protein (Figure 16B).  This further implies that the 
TbpB C-lobe deletion protein is unable to bind transferrin in vitro. 
 In addition, we evaluated the ability of the TbpB C-lobe deletion protein to bind 
transferrin at the cell surface by whole-cell binding assays.  This was done in a TbpA inactivated 
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Figure 14.  TbpB C-lobe deletion is unable to bind transferrin in gonococcal strains.  Whole 
cell lysates of iron-stressed gonococci grown in liquid culture for 4 hours were subjected to SDS-
PAGE and transferred to nitrocellulose.  Blots were probed with HRP-Tf to detect transferrin 
binding by TbpB.  FA19, MCV515, and FA6747 serve as the wild-type TbpB and parent strain 
controls.  Deletion of the TbpB C-lobe in these backgrounds is indicated with C.  FA6815 and 
FA6819 serve as transferrin binding negative controls of gonococcal strains containing tbpB 
gene deletions.  Molecular weight markers are indicated on the right. 
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Figure 15.  Detection of transferrin binding by gonococcal TbpB C-lobe deletion over time.  
The TbpB C-lobe deletion gonococcal strain (FA19 C) was grown under iron-stressed 
conditions in liquid cultures.  Whole cell lysates of the TbpB C-lobe deletion gonococci were 
taken every hour for 4 hours.  Lysates were subjected to SDS-PAGE, transferred to 
nitrocellulose, and probed with HRP-Tf to detect transferrin binding with short (A) and long (B) 
exposures to film.  Samples of FA19 C are indicated by their respective timepoints.  FA19 
serves as the wild-type TbpB and parent strain control.  E. coli N-lobe serves as the TbpB C-lobe 
deletion control for size comparison and transferrin binding negative control.  pUNCH750 serves 
as a positive control for transferrin binding of a tbpB gene deletion in E. coli.  Molecular weight 
markers are indicated on the right and the arrow indicates the TbpB C-lobe deletion. 
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Figure 16.  TbpB C-lobe deletion is unable to bind transferrin in E. coli strains.  Whole cell 
lysates of IPTG-induced E. coli containing plasmids with different C-terminal deletions of 
gonococcal TbpB were subjected to SDS-PAGE and transferred to nitrocellulose.  Blots were 
probed with polyclonal anti-TbpB serum (A) and HRP-Tf to detect transferrin binding by TbpB 
(B).  The previously made pUNCH plasmids (Table 1) are labeled with their respective numbers.  
pUNCH750, 768, 769, and 772 are positive transferrin binding E. coli controls.  pUNCH 770 is 
the negative transferrin binding E. coli strain.  The E. coli TbpB C-lobe deletion constructed in 
the current study is labeled E. coli N-lobe.  FA19 serves as the wild-type TbpB in a gonococcal 
backrgound.  FA6819 serves as a transferrin binding negative control of gonococcal strains 
containing tbpB gene deletions.  Molecular weight markers are indicated on the right and the 
arrow indicates the TbpB C-lobe deletion. 
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background, FA6747, since both Tbps are independently capable of binding transferrin.   To 
ensure that the TbpB protein was being produced at a detectable level in the FA6747 C-lobe 
deletion strain, we used anti-TbpB antibody to detect protein expression.  However, this does not 
provide any information on the cellular localization of TbpB or structural integrity of the protein 
since periplasmic TbpB as well as fragments of TbpB are able to be detected in this assay.  TbpB 
protein expression was able to be detected in the FA6747 TbpB C-lobe deletion strain (Figure 
17A).  However, transferrin binding was not detected in this strain with HRP-transferrin (Figure 
17B), indicating that either the protein being made is unable to bind transferrin or that there is 
not enough protein present on the cell surface, due to degradation, to detect transferrin binding.  
Expression of TbpB and transferrin binding were also analyzed using whole-cell binding assays 
at one hour timepoints taken when growing the cultures under iron-stressed conditions.  
Although an increase of TbpB expression was seen with increasing time and iron-stress (Figure 
18A), no transferrin binding was able to be detected at any of the timepoints (Figure 18B).  
These data suggested that the C-lobe deletion strain is unable to bind transferrin in vivo at the 
gonococcal cell surface. 
C.  Utilization of transferrin is impaired in the TbpB C-lobe deletion 
 To analyze the impact of the TbpB C-lobe deletion on the function of the transferrin iron 
acquisition system, we again used the gonococcal strain MCV515 which has a mutation in TbpA 
that makes it completely dependent on TbpB for the use of transferrin as an iron source.  We 
combined the TbpA mutation with the TbpB C-lobe deletion to determine if the deletion of the 
C-lobe impairs the function of TbpB based on its ability to compensate for the TbpA defect.  We 
examined the growth phenotype of the MCV515 TbpB C-lobe deletion strain on CDM- 
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Figure 17.  Whole-cell binding assays of TbpB C-lobe deletion strains.  Iron stressed whole 
gonococci were applied to nitrocellulose and probed with polyclonal anti-TbpB serum (A).  
Surface transferrin binding was examined by probing with HRP-Tf (B).  Each lane is labeled 
according to strain name.  FA6905 serves as TbpB-negative and Tf binding-positive control and 
FA6815 serves as a TbpB-positive and Tf binding-negative control.  FA19 and FA6747 are the 
parental strains for the TbpB C-lobe deletion in these backgrounds, indicated by C.  
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Figure 18.  Whole-cell binding assays of TbpB C-lobe deletion strains over time.  Iron 
stressed whole gonococci were applied to nitrocellulose and probed with polyclonal anti-TbpB 
serum (A).  Surface transferrin binding was examined by probing with HRP-Tf (B).  Each lane is 
labeled according to strain name.  FA6905 serves as TbpB-negative and Tf binding-positive 
control and FA6815 serves as a TbpB-positive and Tf binding-negative control.  FA19 and 
FA6747 are the parental strains for the TbpB C-lobe deletion in these backgrounds, indicated by 
C.  Samples of FA6747C were taken every hour for 4 hours, indicated by their respective 
time, to detect changes in TbpB expression and Tf binding over time.  
92 
 
 
 
 
 
 
 
 
 
 
 
 
  
Tf 
TbpB 
F
A
1
9
 
F
A
6
9
0
5
 
F
A
6
8
1
5
 
F
A
6
7
4
7
 
F
A
6
7
4
7
 
C
 0
 h
o
u
r 
F
A
6
7
4
7
 
C
 1
 h
o
u
r 
F
A
6
7
4
7
 
C
 2
 h
o
u
rs
  
F
A
6
7
4
7
 
C
 3
 h
o
u
rs
 
F
A
6
7
4
7
 
C
 4
 h
o
u
rs
 
F
A
1
9
 
C
 
B. 
A. 
93 
 
transferrin and found that transferrin utilization was reduced, compared to the parental MCV515 
strain (Figure 19).  However, growth was not completely abolished in the C-lobe deletion strain, 
as seen in the negative control MCV516 which is the parental strain with the deletion of TbpB 
(Figure 19).  This indicates that some function of TbpB is retained in the C-lobe deletion protein. 
To further characterize the growth phenotype, the MCV515 TbpB C-lobe deletion strain 
was plated on CDM containing different percent saturated transferrin in parallel with the HA 
epitope insertions 4, 5, and 8 in the same background.  The saturation percentages of transferrin 
used were 5, 10, 20, 30, and 50.  The three HA epitope insertions and the TbpB C-lobe deletion 
showed diminished growth compared to the parent strain on all plates, even the 50% saturated 
transferrin (Figure 20).  However, none of them exhibited the same phenotype as the negative 
control, MCV516, which was unable to grow at all (Figure 20).  Therefore, although all of these 
mutations impaired the function of TbpB, none of them abolished its function in compensating 
for the TbpA defect.  Interestingly, the TbpB C-lobe deletion strain behaved most like the HA4 
N-lobe insertion rather than the HA8 C-lobe insertion (Figure 20).  This indicated that deletion of 
the TbpB C-lobe caused a more significant effect on TbpB function compared to disruption of 
the C-lobe lobe by an insertion, further confirming the role of the C-lobe in the proper function 
of TbpB.  Despite the fact that the TbpB C-lobe deletion protein is unable to bind transferrin by 
western blot and whole-cell binding assays, some of its role in transferrin utilization is retained. 
 
III.  Discussion 
 The recent crystal structure of meningococcal TbpB confirmed the bilobed structure of 
the protein.  However, the involvement of the individual lobes in the function of neisserial TbpB  
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Figure 19.  TbpB C-lobe deletion is able to support limited growth.  Samples of the TbpB C-
lobe deletion in the MCV515 gonococcal background were plated onto CDM medium containing 
30% saturated Tf as the sole iron source.  MCV515 and MCV516 serve as the positive and 
negative control strains, respectively.  MCV833 serves as a control for a C-lobe TbpB mutation 
that affects transferrin binding and utilization.  
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Figure 20.  TbpB C-lobe deletion behaves similarly to the TbpB HA epitope insertions.  
Samples of the TbpB C-lobe deletion in the MCV515 gonococcal background were plated in 
parallel with the TbpB HA epitope insertion mutants in the same background onto CDM medium 
containing different levels of saturation of Tf.  Saturation percentages used were 5 (A), 10 (B), 
20 (C), 30 (D), and 50 (E).   MCV515 and MCV516 serve as the positive and negative control 
strains, respectively.  MCV829 and MCV830 have HA epitope insertions in the TbpB N-lobe 
and MCV833 has an HA epitope insertion in the TbpB C-lobe, all of which affect transferrin 
binding and utilization.  
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is still debated.  Previous in vitro studies using gonococcal TbpB showed that only regions in the 
N-lobe are responsible for high affinity transferrin binding (47) while in vivo studies 
demonstrated that both lobes are necessary for function of TbpB in the native gonococcus (57).  
The purpose of this study was to determine the role of the C-lobe in the transferrin iron 
acquisition function of gonococcal TbpB.  To accomplish this, a precise, full deletion of the C-
lobe of TbpB was constructed and characterized.  Western blot analysis indicated that deletion of 
the C-lobe causes degradation of the TbpB protein in both gonococci (Figures 10, 11, and 13) 
and E. coli (Figure 12).  It also revealed that the minimal N-lobe TbpB protein not broken down 
in these backgrounds is unable to bind transferrin (Figures 14, 15, and 16).  Additionally, the N-
lobe TbpB protein was incapable of binding transferrin at the cell surface in whole-cell binding 
assays (Figures 17 and 18).  When transferrin utilization was tested, the N-lobe was able to 
support very limited growth on human transferrin as an iron source (Figures 19 and 20), which 
was contradictory to the transferrin binding assays. 
Deletion of the C-lobe of TbpB resulted in the degradation of the expressed protein, 
which consists of the N-terminal half and linker region connecting the two lobes.  Degradation 
was seen with both liquid and plate cultures, indicating that this outcome is not affected by the 
method of growth.  This was surprising since previous deletion mutants FA6815 and FA6819 
(5), which result in shorter peptides than the C-lobe deletion and incapable of binding transferrin, 
are still expressed at wild-type levels.  These results indicate that a specific characteristic of the 
C-lobe deletion protein created in the current study causes it to be broken down.  The 
degradation of the protein in E. coli is also peculiar since previous C-terminal deletion mutants, 
both longer and shorter, were properly expressed in this bacterium (47).  Breakdown of the 
protein in E. coli shows that degradation of the protein is not restricted to the native gonococcus, 
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indicating a general reason common to both bacterial species.  Furthermore, since the E. coli C-
lobe deletion construct does not contain the native gonococcal TbpB signal sequence, it remains 
in the cytoplasm where it gets degraded.  Although it is impossible to determine if the 
gonococcal TbpB C-lobe deletion peptide is degraded in the cytoplasm or periplasm, it is likely 
that the TbpB protein is also broken down in the cytoplasm of the gonococcus before it is able to 
be transported across the inner membrane. 
Degradation of the TbpB C-lobe deletion protein could occur through several different 
methods.  First, the structure of the full length N-lobe alone could be unstable causing limited or 
improper folding of the protein which leads to the degradation of the protein.  Additionally, the 
presence of the linker region of the protein could be responsible for the degradation.  The two 
lobes of TbpB are connected by a short, unstructured linker region which was included in the 
construct of the C-lobe deletion gene.  With no fragment of the C-lobe to form some kind of 
structural protection, the linker region would be exposed in the cellular environment.  This could 
increase the instability of the protein or be available for digestion by proteases, leading to the 
degradation of the entire protein.   
Although we hypothesized that the deletion of the C-lobe would only slightly affect 
transferrin binding since the N-lobe remained intact, the N-lobe protein produced by the deletion 
of the C-lobe was not able to bind transferrin on western blots in either a gonococcal or E. coli 
background (Figures 14, 15, and 16).  Although a longer exposure demonstrated some weak 
transferrin binding, it was negligible compared to wild-type and may have been nonspecific.  The 
previously made TbpB constructs in E. coli showed that the only C-terminal deletion affecting 
transferrin binding removed all of the C-terminal half as well as a portion of the N-terminal half 
(47).  The next smaller deletion included the beginning of the C-terminal half and transferrin 
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binding was retained with this construct.  Therefore, the C-lobe deletion of TbpB created in this 
study is in between these two constructs and its transferrin binding capability could only be 
postulated.  The minimal expression of stable TbpB in the C-lobe deletion strains could account 
for the absence of detectable transferrin binding.  However, the detection of TbpB using HRP-
transferrin is much more sensitive than the TbpB antibodies.  If the protein was capable of 
specific binding to transferrin, we should have been able to detect it on the western blot with 
HRP-transferrin.  Additionally, due to the instability of protein demonstrated by its degradation, 
the structure of TbpB that is retained during denaturation and SDS-PAGE analysis could also 
have been affected by the deletion of the C-lobe, diminishing its ability to bind transferrin on a 
western blot even if it were capable.  The western blot analyses examining the transferrin binding 
of the TbpB C-lobe deletion protein revealed that the gonococcal TbpB N-lobe is incapable of in 
vitro transferrin binding. 
Transferrin binding by the TbpB C-lobe deletion protein at the cell surface was also not 
detected in the whole-cell binding assays.  The instability of the N-lobe portion of TbpB 
resulting in the decreased expression of the protein could account for the inability of transferrin 
binding to be detected.  The whole-cell binding assay may also not be sensitive enough to detect 
the diminished expression of TbpB on the cell surface, although previous studies have shown 
that this assay is capable of detecting reduced transferrin binding by TbpB (5, 51, 57).  Although 
alternative explanations exist, these results demonstrate that the TbpB C-lobe deletion protein is 
also unable to bind transferrin in vivo, and together with the in vitro binding data, suggest that 
the gonococcal N-lobe construct generated in the current study is not capable of specific binding 
transferrin independent from the C-lobe. 
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A previous study examining the functional domains of TbpA involved in transferrin 
binding and utilization demonstrated that in one TbpA mutant, wild-type TbpB provided a 
compensatory function allowing the use of transferrin as an iron source (243).  This TbpA 
mutant was used to determine the effect of the C-lobe deletion in the function of TbpB in the 
gonococcus.  Since absolutely no transferrin binding by the protein at the cell surface was 
detected, it was surprising to see that the TbpB C-lobe deletion protein could compensate for the 
TbpA defect in background strain MCV515 strain and growth was still weakly sustained by 
transferrin.  One theory to explain this is that the whole-cell binding assay is not sensitive 
enough to detect the little transferrin binding that occurs at the cell surface by the C-lobe deletion 
protein.  However, this small amount of transferrin binding by TbpB is able to support growth of 
the gonococci, but at a reduced capacity.  Additionally, this could be explained by an alternative 
function of TbpB in the acquisition of iron from transferrin that is independent of TbpB’s ability 
to bind transferrin.  An interaction between TbpA and TbpB could be involved in the 
internalization and utilization of transferrin-bound iron and this alternative function is retained in 
the TbpB C-lobe deletion protein.  Therefore, deletion of the C-lobe does not interrupt this 
interaction and the N-lobe is able to compensate for the TbpA defect independently. 
In summary, deletion of the C-lobe of TbpB caused degradation of the protein in a 
bacterial species and cellular localization independent manner.  No in vitro or in vivo transferrin 
binding by the C-lobe deletion protein was detected under normal assay conditions.  This 
supports the importance of the C-lobe in TbpB’s function of binding to transferrin.  Finally, the 
C-lobe deletion protein supported limited growth of the gonococci on transferrin in a manner that 
is independent of the transferrin binding function of the protein.  Our results indicated that both 
N- and C-terminal halves must be present to achieve wild-type function of the TbpB protein. 
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CHAPTER 5:  Summary 
 
 Neisseria gonorrhoeae is an obligate human pathogen and extremely well adapted to 
survive in the human host.  It is responsible for causing the sexually transmitted infection 
gonorrhea, which is the second most commonly reported infectios disease in the United States 
(37).  The third generation cephalosporins are the only recommended treatment due to rise in 
resistance to previously effective antibiotics but increases in cephalosporin resistance have been 
reported (9, 38),  with the first high level clinical resistance reported in early 2011 (147).  
Treatment options are rapidly diminishing and vaccine development against N. gonorrhoeae has 
been unsuccessful thus far.  Therefore, the development of new preventative and therapeutic 
methods is imperative.  Transferrin binding proteins (Tbps) are appealing vaccine candidates 
because they are surface exposed, not highly variable, expressed in all clinical isolates, and 
necessary for the establishment of infection in human males (50, 130).  TbpB, in particular, has a 
more significant role in producing an antibody response in mouse immunizations with 
gonococcal proteins (156) and in meningococcal infections (113, 151, 152, 168)  as well as other 
bacterial infections (139, 171, 222).  Understanding TbpB structure and function within the 
gonococcus is necessary for its potential use in the development of a treatment or vaccine. 
The gonococcal transferrin receptor complex is composed of two outer membrane 
proteins.  TbpA is a TonB dependent outer membrane transporter and TbpB is the associated 
lipoprotein.  Although it is not essential for transferrin utilization, TbpB is able to distinguish 
between free and iron-bound transferrin, increasing the efficiency of iron uptake (51).  However, 
103 
 
its exact role in transferrin-iron internalization has not yet been fully determined.  TbpB is fully 
surface exposed and anchored in the outer leaflet of the outer membrane (57).  The mechanism 
of TbpB export to the outer membrane and localization to the outer leaflet has not yet been 
identified.  Internal homology and crystal structure studies of neisserial TbpB revealed the 
bilobed structure of the protein.  Although the N-lobe has been shown to be involved in 
transferrin binding, the role of the C-lobe has been debated and remains controversial (47, 57, 
162, 164, 213).  
The overall goals of this study were to identify the transport mechanism of TbpB to the 
outer membrane and further delineate the role of the C-lobe of TbpB in transferrin binding and 
utilization.  Since the process of TbpB export is unknown, isolating and characterizing the 
factors involved in the transport of TbpB could present new therapeutic targets.  Structure-
function analyses of TbpB would provide valuable insight into its role in the transferrin iron 
acquisition system and could lead to the development of new therapeutic agents.  Both objectives 
can lead to a better understanding of the pathogenesis of the microorganism. 
Lipoprotein export in E. coli is accomplished through the function of the Lol system 
which is well conserved among Gram-negative bacteria.  However, neisserial lipoproteins do not 
seem to be transported through the Lol system, indicating the presence of Lol-independent 
transport machinery (214).  Additionally, unlike E. coli, Neisseria produce lipoproteins that are 
surface exposed and anchored in the outer leaflet of the outer membrane.  The protein(s) 
involved in the translocation of lipoproteins across the outer membrane have also not yet been 
identified.  We sought to characterize the gonococcal lipoprotein transport machinery through 
mutagenesis using a transposon library.  We were able to isolate three potential TbpB export 
deficient mutants but only one, mutant 4912, showed promise after classification of the 
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transposon insertion site.  The disrupted gene, NG2117, encodes a possible MSD protein in an 
ABC transport system, which is an integral component of an ABC transporter.  Since an ABC 
transporter is part of the Lol system and is most likely required for lipoprotein detachment from 
the inner membrane, NG2117 could be involved in lipoprotein export in N. gonorrhoeae. 
Our protease accessibility assays revealed surface exposure of TbpB in this mutant, and 
reexamination of mutant 4912 samples revealed multiple genotypes within the population.  
Therefore, no conclusions can be drawn from the data presented in the current study since the 
samples were a mixed population with different lipoprotein export phenotypes.  Further studies 
are needed to isolate an isogenic population of the NG2117 mutant or create a deletion of the 
NG2117 protein and characterize the surface exposure of TbpB in that mutant.  Although 
conclusions could not be made, our data identified a protein that has the potential to be involved 
in gonococcal lipoprotein export. 
Using the transposon library, we have screened over 14,000 mutants and have likely 
exhausted this method of finding the TbpB export system, due to either the limitation of the 
library or potential lethal nature of interrupting the lipoprotein transport process.  Since deletion 
of the Lol proteins in E. coli is lethal (142, 199, 200), disruption of the lipoprotein transport 
system in N. gonorrhoeae may also be lethal.  Blocking the transport of TbpB and other 
lipoproteins could provide potential therapeutic effects.  Therefore, identifying the mechanism of 
transport of TbpB to the outer leaflet of the outer membrane could present new treatment and 
vaccine targets. 
Previous in vitro studies using recombinant proteins and western blot analysis that 
defined a minimal domain necessary for transferrin binding determined that only conserved 
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regions in the N-terminal half of gonococcal TbpB were involved in high affinity transferrin 
binding (47).  Conversely, studies using whole, intact gonococcal cells demonstrated a role of the 
C-lobe in binding and utilization of transferrin in vivo at the cell surface (57).  We sought to 
further delineate the role of the C-lobe in gonococcal TbpB function by constructing and 
characterizing a full, precise C-lobe deletion, both in vitro and in vivo.  Based on the previous 
studies, we hypothesized that deletion of the C-lobe would impair TbpB function but some 
transferrin binding by the N-lobe would be retained. 
However, we showed that deletion of the C-lobe of gonococcal TbpB results in the 
degradation of the protein.  Unfortunately, this degradation of the TbpB C-lobe deletion protein 
obfuscates the transferrin binding ability of the N-lobe but our results indicate what little N-lobe 
protein remains intact is not capable of binding transferrin.  The method of degradation is 
unknown and specific to this construct since other TbpB deletions are stably expressed.  It seems 
likely that the presence of the unstructured linker region is responsible for initiating breakdown 
of the protein, and the absence of detectable transferrin binding is a result of this instability.  
Interestingly, our studies also demonstrated that some function of TbpB is retained in the C-lobe 
deletion protein when transferrin utilization is analyzed by cell growth, despite the lack of 
detectable transferrin binding.  This could be explained by the proper expression and export of a 
minimal amount of TbpB C-lobe deletion protein that is still capable of binding tranferrin.  
Additionally, an alternative function of TbpB, through an interaction with TbpA, may aid in the 
use of transferrin-bound iron and is independent of its function in transferrin binding. 
Overall, our studies on the deletion of the TbpB C-lobe indicated that both lobes of TbpB 
contribute to the proper function of the protein, which may go beyond transferrin binding.  
Identifying the functional domains of TbpB is essential in exploring their potential as therapeutic 
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targets and vaccine candidates.  Price et al. demonstrated recombinant gonococcal Tbps 
conjugated to cholera toxin B subunit are capable of inducing an antibody response in mice, and 
TbpB generated a greater response than TbpA (156).  The results presented here could have an 
impact on development of TbpB-based vaccine against N. gonorrhoeae by providing insight into 
the important structural features involved in the function of TbpB, potentially leading to the 
identification of new therapeutic targets.  Also, antibodies directed against specific epitopes on 
the TbpB protein could have differential effects depending on the location of the epitope.  Our 
studies have provided insight into the localization of TbpB to the outer membrane and may 
potentially be applied to all lipoprotein export in Neisseria and other Gram-negative bacteria 
lacking a functional Lol system.  Additionally, our studies further characterized the structure-
function relationship of the TbpB lobes, which may be extended to other bilobed, lipid-modified 
receptor proteins of Neisseria.  
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